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Solid tumours are characterized by a complex structure comprised of extracellular matrix, 
neoplastic cells and stromal cells, each presenting a barrier to conventional anticancer 
chemotherapy as well as carrier-mediated drug delivery. Poor penetration of therapeutics into the 
interstitial tumour microenvironment remains a challenge, with drugs accumulating primarily in 
the regions of tumours that are situated closer to blood vessels. Bacteriophages do not infect 
eukaryotic cells, yet they have been shown to penetrate mucosal barriers, including multiple 
layers of epithelial cells and endothelium. In this work, we used NIH3T3 fibroblast and HT29 
colon adenocarcinoma multicellular spheroids to represent the stroma and parenchyma of solid 
tumours and then to examine infiltration of bacteriophages as a means of delivering therapeutic 
cargo. By using phage display technology to decorate the surface of λ bacteriophage with 
epidermal growth factor (EGF), we compared the cell-phage interactions between wildtype 
phages and EGF-displaying phages, including the assessment of phages’ capacity to traverse the 
tumour interstitium, to be subjected to cell internalization and their effects on spheroid growth. 
Both wildtype and EGF-displaying λ phages were observed to adhere to the HT29 and NIH3T3 
spheroids and to internalize into cells as early as 30 min following administration. EGF-phage 
treatment also slowed HT29 spheroid growth – demonstrating a delay in initial aggregation and 
formation of loosely-organized structures that led to much smaller spheroid formation in the 
latter stages of growth. These results support the potential for the therapeutic employment of 
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Chapter 1: Introduction 
1.0 Perspective 
Drug delivery technology has advanced in the recent years; however, the development of an 
efficient delivery system into solid tumours is still much needed. Ideally, this system would 
confer: i) specific targeting to minimize drug-associated systemic toxic effects; ii) effective 
extravasation into the tumour interstitium; iii) effective diffusion through the dense tumour 
extracellular matrix; and iv) internalization into desired cells to deliver drug payload. Various 
nanocarriers have been examined for their potential to improve the bioavailability and 
preferential accumulation in the tumour site. Oftentimes, these particles are found situated 
closest to the vessel from which they extravasated from in vivo and do not achieve effective 
infiltration into the tumour (Tannock et al., 2002).  
Bacteriophages (phages), which are bacterial viruses, have a strong potential as a drug delivery 
vehicle and offer new avenues in anticancer therapy. Tumour-homing peptides and ligands of 
overexpressed receptors on tumour cell surfaces can be fused to phage capsid proteins for 
targeting. Phages are unlikely to undergo alterations in their tropism, which is a major concern 
with the exploitation of oncolytic viruses in anticancer therapy (Raja et al., 2018). Phages have 
demonstrated the ability to bypass the epithelium and endothelium and can accumulate in various 
mammalian tissues and organs following their administration (Dabrowska et al., 2005). 
Additionally, the production of phages is relatively low, and cost of phage purification appears to 
be declining with the advancements in technology (Mancuso, Shi, & Malik, 2018). Although 
transfection with phages for anticancer therapy has been explored, the interaction of phages with 
neoplastic cells in 3-dimensional cell culture has not yet been described to date.  
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This project was an exploratory study assessing the potential of bacteriophages as a tumour 
nanocarrier system. Multicellular spheroids were used to model the tightly-packed tumour 
interstitium and responses to the application of λ phages were described. Phages displaying 
ligands for overexpressed receptors were also examined in their accumulation in spheroids.  
1.1 Solid tumours and the tumour microenvironment 
The complex and dynamic processes of tumourigenesis highlight the need for the development 
of effective treatment. Different cellular and non-cellular elements of the tumour 
microenvironment have hindered the applications of emerging antineoplastic, low-weight 
molecules. Cellular resistance to anticancer drugs is caused by mechanisms such as drug export, 
changes in drug metabolism and mutations in drug targets that activate survival signaling 
pathways or inactivate death signaling pathways (Gottesman, 2002). Effective drug delivery adds 
another layer of complexity in treatment due to the pathophysiology of the tumour 
microenvironment. This includes irregular vasculature that generates considerable variations 
throughout the tumour microenvironment, creating regions that are hypoxic and poorly perfused 
(Mueller-Klieser, 1997). Different exposures to nutrients and oxygen cause variable proliferation 
rates in cells that then respond differently to drugs (Khawar, Kim, & Kuh, 2015). To achieve 
sufficient cytotoxicity in tumour cells, systemically administered anti-cancer drugs need to reach 
the tumour vasculature network, extravasate across the vessel into the interstitial space and reach 
each tumour cell at a pharmacologically-effective dose (Dreher et al., 2006b; Sriraman, 
Aryasomayajula, & Torchilin, 2014; Ying et al., 2010). For successful cancer treatment, all 
tumour cells must be accessible by the drug, otherwise survival of a few cells could lead to 
tumour recurrence for the patient. This is difficult for most conventional chemotherapeutic drugs 
to achieve. Hence, much attention has been directed to the development of novel drug delivery 
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methods for which optimal surface physio-chemical properties can be conferred to maximize 
tumour accumulation. Components of the tumour microenvironment that impede the therapeutic 
course of drug delivery are further discussed below.  
1.1.1 Extracellular matrix (ECM) 
A major component of the tumour stroma is the extracellular matrix (ECM), which is a network 
of collagen, elastin fibers, proteoglycans and hyaluronic acid present in the basement membrane 
and the looser matrix of the interstitial space (Yue, 2014). ECM provides structural integrity for 
tissues, modulates cell function, and serves as reservoirs for growth factors and signaling 
molecules (Yue, 2014). ECM components, however, will physically impede immune cells and 
therapeutic drugs from effectively penetrating into the tumour. Furthermore, ECM composition 
will be altered as proteins and growth modulators become overexpressed in the tumour 
microenvironment. Such molecules include osteoblast-specific factor 2 (OSF-2), which is 
involved in cell adhesion (Bao et al., 2004; Malanchi et al., 2012); versican, a large chondroitin 
sulfate proteoglycan (Ricciardelli et al., 1998); and hyaluronan, a glycosaminoglycan that is 
often deposited in solid tumour and has been implicated in epithelial-to-mesenchymal transition 
(EMT) and drug resistance (Kultti et al., 2014; Toole & Slomiany, 2008). Notably, collagen, a 
protein of the connective tissue that provides tensile strength, increases in its deposition over 
time with tumour progression and serves as a primary barrier against drug penetration (Cox et 
al., 2013; Provenzano et al., 2008). Collagen accumulation has been associated with ECM 
remodelling, which is caused by the aberrant expression of the enzyme lysyl oxidase (LOX). 
LOX mediates collagen cross-linking resulting in enhanced tumour cell survival, metastasis and 
overall tumour stiffness (Cox et al., 2013; Provenzano et al., 2008; Wang, Hsia, & Shieh, 2017). 
Netti et al. demonstrated the correlation between an extended collagen network and poor 
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penetration of model proteins, IgG and BSA, using xenografted tumours from four different 
tumour lines: human colon adenocarcinoma (LS174T), human glioblastoma (U87), human soft 
tissue sarcoma (HTS 26T) and murine mammary carcinoma (MCalV) (Netti, Berk, Swartz, 
Grodzinsky, & Jain, 2000). Accumulation of these proteins was poorer in U87 and HTS26T 
tumours. Histological staining showed that collagen and proteoglycan in these two tumours were 
well-defined and organized, likely contributing to resistance to macromolecular drug penetration. 
Enzymes such as collagenase have been used to digest these ECM proteins to improve 
penetration of nanoparticles (Netti et al., 2000; Svishchev & Goncharov, 1990).  
1.1.2 Interstitial fluid pressure  
The irregular vasculature in solid tumours consists of excessively-branched, dilated, leaky 
vessels with loosely-attached pericytes (Tredan, Galmarini, Patel, & Tannock, 2007). Vessels are 
highly heterogenous in tumours and can cause variable blood flow to tumour tissues – this limits 
oxygen and nutrient access for cells, ultimately influencing metastasis and sensitivity to drug 
treatment to poorly perfused cells (discussed below) (Aznavoorian et al., 1990; Vaupel, 
Kallinowski, & Okunieff, 1989). Drugs diffuse down their concentration or pressure gradients, 
but as the network of vessels have high resistance to blood flow, drugs may instead be pulled 
into tissues via osmotic forces (Sriraman et al., 2014). Moreover, these irregularities in tumour 
tissues can be exacerbated by the lack of a proper lymphatic drainage, resulting in the 
accumulation of fluids and increased interstitial fluid pressure (IFP) (Ferretti et al., 2015; Padera 
et al., 2002). IFP can vary between tumours of the same histological type, each then responding 
differently to chemotherapy or radiation (Curti et al., 1993). Normal interstitial pressure is close 
to atmospheric, the excess pressure ranging from 1-3 mm Hg. These incremental values can be 
elevated to up to 100 mm Hg in tumour tissues, which often correlates to poor survival and 
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treatment responses in patients (Kłosowska-Wardęga et al., 2009; Milosevic et al., 2004; Sen et 
al., 2011; Simonsen et al., 2012; Willett et al., 2004). IFP is also directly associated with tumour 
angiogenesis, whereby pro-angiogenic and anti-angiogenic factors are upregulated and 
downregulated in tumours, respectively (Huang & Bao, 2004). Blocking angiogenesis has shown 
to improve drug penetration against the pressure gradient (Kłosowska-Wardęga et al., 2009; 
Tong et al., 2004; Willett et al., 2004). Angiogenesis can be downregulated by inhibiting 
vascular endothelial growth factor (VEGF), which is a family of secreted polypeptides that 
regulates blood vessel formation, or by blocking platelet-derived growth factor receptor (PDGF-
R), which is a tyrosine-protein kinase that promotes blood vessel development when bound by a 
growth factor (Kłosowska-Wardęga et al., 2009). PDGF-R is localized in the cells of 
mesenchymal origin, such as neurons and vascular smooth muscle cells, and is often 
overexpressed in tumour cells (Shen et al., 2012). Imatinib is a drug that binds to p-PDGFR-β 
and has been shown to downregulate VEGF, reduce IFP and increase tumour oxygenation 
(Vlahovic et al., 2006). Similarly, the VEGF-specific antibody bevacizumab has shown to 
decrease microvascular density in five of six patients with rectal tumours (Willett et al., 2004). 
1.1.3 Hypoxic core  
Gradients of nutrients and oxygen levels are established in tumour tissues, with rapidly 
proliferating cells situated closer to the vasculature where levels are highest (Tredan et al., 2007). 
In well-vascularized tissues, cells are localized within 50-100 µm of perfused blood vessels; this 
distance can increase up to 200 μm for tumour cells, severely impairing blood flow and poor 
oxygen delivery to cells in tumour tissues (Bilski, Daub, & Chignell, 2002). One study revealed 
that hypoxic (≤5 mmHg) and anoxic values were reached 70-80 µm and 150 µm away from the 
vessel, respectively (Helmlinger et al., 1997). Hypoxia is associated with the malignant 
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phenotypes of tumours, inducing genes that express angiogenic and metastatic factors (Harada, 
Kizaka-Kondoh, & Hiraoka, 2005). Extracellular acidity of pH 6.5 – 7.0 is also a common 
feature in areas distal from the vasculature in tumours and is a direct result of accumulated CO2 
and other metabolites produced from anaerobic glycolysis, such as lactic acid (Vaupel, 2004; 
Vukovic & Tannock, 1997). In tumours, pH was shown to have dropped by a factor of 0.32, 10 
to 100 µm away from the vessel wall (Helmlinger et al., 1997). Conventional anticancer agents 
have limited access to these cells due to irregular blood flow, poor rate of diffusion and binding 
to other tissue components; thus they are often detected at the rim of the tumour, if any at all 
(Jain, 1990, 2012; Minchinton & Tannock, 2006; Seynhaeve et al., 2007; Tredan et al., 2007; 
Vukovic & Tannock, 1997). Furthermore, the cytotoxicity of chemotherapeutic drugs is reduced 
in hypoxic and acidic environments. Cytotoxicity of doxorubicin has been shown to be less 
substantial in low-pH-adapted cells than in normal cells, due to the transmembrane pH gradient 
that is established in these cells (Gerweck, Kozin, & Stocks, 1999; Yao et al., 2005). 
Additionally, low pH has been shown to direct cells into the G1 phase, rendering them more 
resistant to the action of mioxantrone and topotecan (Vukovic & Tannock, 1997). Secondary 
metabolites produced by glycolysis have also been targeted as a therapeutic strategy; Sonveaux 
et al. showed that this can be achieved by targeting lactate transporters, such as MCT1, resulting 
in the effective inhibition of hypoxia-inducible factor-1 (HIF-1)-dependent angiogenesis in 
endothelial cells (Sonveaux et al., 2012).  
1.2 Solid tumour therapy  
Although surgical excision is the most widely used form of tumour therapy, it is most effective 
when the tumour is still considered small and confined to a limited area. This is, however, not an 
effective method for large, invasive and metastatic tumours, whereby resection of surrounding 
7 
 
normal tissues can lead to organ dysfunction (Gavhane et al., 2011).  Radiation is another 
commonly employed method for inoperable solid tumours, such as lung cancer, but the potential 
co-injury of normal tissues must be considered. This can result in toxic effects such as bone 
marrow suppression and inflammation of the surrounding tissues for the patient (Barker et al., 
2015; Ramnath et al., 2013). Conventional chemotherapeutic agents function mostly by targeting 
actively-replicating malignant cells and are often combined with radiation and surgery to 
increase the effectiveness of treatment. However, this mechanism is also non-specific and often 
harms normal cells of the bone marrow, gastrointestinal tract, hair follicles and gonads (Gavhane 
et al., 2011). Therefore, specific targeting remains the desired goal since it would ensure 
increased effectiveness of anticancer agents, driving the research into the development of 
alternative drug delivery systems and methods (Housman et al., 2014). New methods of payload 
delivery have been explored, such as nanoparticles (Rizvi & Saleh, 2018), liposomes (Alavi, 
Karimi, & Safaei, 2017; Kibria et al., 2013; Torchilin, 2005), and microspheres (Varde & Pack, 
2004). These systems based on passive or active tumour targeting have been considered 
promising, but many are still limited by their larger size (Dreher et al., 2006a; Maeda, Sawa, & 
Konno, 2001; Yuan et al., 1994). Extravasation into the tumour interstitium remains a challenge, 
as liposomes of 100 nm have failed to extravasate into the SKOV-3 (human ovarian carcinoma) 
(Kong, Braun, & Dewhirst, 2001) and B16BL6 (melanoma) tumours in mice (Seynhaeve et al., 
2007). A better strategy for targeting is therefore needed. 
1.3 Cell receptors   
Tumour cells are equipped with cell-surface receptors, including/and not limited to HLA 
antigens, cytokine receptors and growth factor receptors (Richter & Zhang, 2005). The 
overexpression of cellular receptors has long been exploited in targeting cancer therapeutics, 
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especially the inhibition of growth factor receptors (Richter & Zhang, 2005). A myriad of 
potential molecular targets have been identified in cancer therapeutics. A widely-known example 
is the HER-2/neu receptor, which can be inhibited by Herceptin® – an FDA-approved drug used 
for the treatment of patients with HER-2/neu-positive breast and gastric tumours (Yu & Hung, 
2000).  Currently marketed drugs include imatinib for myelogenous leukemia (Sacha, 2014), 
cetuximab for EGFR-overexpressing metastatic colorectal cancer (Wong, 2005) and 
bevacizumab for targeting VEGF of colorectal cancer (Ranieri et al., 2006). Gashaw et al. listed 
the key features of ideal drug targets: 1) they are critical in the perpetuation of cancer cells (not 
just implicated in the early stages of tumourigenesis); and 2) they are not critical in the function 
of normal cells (Gashaw et al., 2012). Moreover, they should be expressed at higher levels, if not 
exclusively, in the targeted tumour cells. Of the many growth factor receptors, receptor tyrosine 
kinases (RTKs) have been implicated in a wide range of cancers. ErbB family members are 
RTKs that are well-known targets in cancer therapy that have been implicated in the cancers of 
the breast, lung, colon, stomach, pancreatic, ovary, brain, prostate and kidney (Inchley, 1969). 
Small molecule tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) have been 
approved for use against ErbB family members (Richter & Zhang, 2005).  
1.3.1 Epidermal growth factor receptor and other ErbB family members 
Despite expression in normal cells, the epidermal growth factor receptor (EGFR, also known as 
ErbB1, HER1) is a transmembrane glycoprotein that has become an attractive target in cancer 
therapy, as it is often overexpressed in epithelial tumours and contribute to tumour progression. 
EGFR modulates growth, signaling, differentiation, adhesion and migration of cancer cells [68, 
69]. Higher expression and ligand-independent signaling mutations of EGFR have been 
implicated in many cancer cells, including metastatic colorectal cancer cells, glioblastoma 
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(Emlet et al., 2014), pancreatic cancer (Oliveira-Cunha, Newman, & Siriwardena, 2011), and 
breast cancer (Yu & Hung, 2000). ErbB family members consist of not only EGFR, but also 
ErbB2 (HER2), ErbB3 (HER3) and ErbB4 (HER4), which are all structurally related. Each is 
composed of an extracellular ligand binding domain, transmembrane domain, tyrosine kinase 
domain, and a tyrosine-containing C-terminal tail (Fig. 1) (Wieduwilt & Moasser, 2008). EGFR 
and ErbB4 can each be bound by a ligand and autophosphorylated through intracellular tyrosine 
kinase domains. ErbB2, however, does not bind to ligands directly but is the preferred 
dimerization partner for EGFR (Graus-Porta et al., 1997). ErbB3 does not possess intrinsic 
tyrosine kinase activity but signal transduction can occur through dimerization with ErbB2 (Citri, 
Skaria, & Yarden, 2003; Shi et al., 2010; Telesco et al., 2011). There are various ligands that 
bind to the extracellular ligand-binding domain of EGFR that ultimately contribute to the 
signaling diversity of EGFR pathways: epidermal growth factor (EGF), transforming growth 
factor-α (TGF-α) and amphiregulin (Xu et al., 2005). Neuregulin-1 and neuregulin-2 can bind to 




Upon binding of a ligand, EGFR dimerizes, which is an essential step for the activation of the 
protein-kinase in the cytosolic domain and the subsequent phosphorylation of the tyrosine 
residues on the adjacent dimer partner (Fig.1). The tyrosine phosphorylation of EGFR creates 
binding sites for Grb2 and Src homology 2 (Shc2), activating downstream signal-transduction 
events, such as the Ras/MAPK, PLCγ1/PKC, PI(3)kinase/Akt, and STAT pathways. This 
consequently alters cellular physiology and gene expression (Wieduwilt & Moasser, 2008). Gene 
expression may also be influenced by ErbB family members that escape the early endosomes and 
localize in the nucleus, although the mechanism is currently unclear (Ni et al., 2001; Xie & 
Hung, 1994).  Activated receptors bound by ligands are most likely internalized via clathrin, 
whereby the receptors detach from the clathrin-coated pits and are directed to the lysosomes for 
degradation (Sorkin, 2001; Wang, Villeneuve, & Wang, 2005). Unbound EGFR is recycled more 
Figure 1: Schematic diagram of receptor tyrosine kinase (RTK). The extracellular binding 
domain of receptor tyrosine kinase binds to ligands, which can cause the receptor to dimerize 
with another RTK. This activates the kinase activity in the cytosolic domain of the RTK and 
induces auto-phosphorylation of the adjacent dimerization partner. 
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rapidly to the surface. Ligand-bound EGFR may either be degraded in the lysosomes or de-
ubiquintinated then recycled, depending on the specific receptor-ligand combination (French et 
al., 1995; Herbst et al., 1994). EGFR heterodimerization with ErbB2 can assist in the evasion of 
the lysosome; these receptors are recycled to the cell surface instead, increasing EGFR surface 
density and consequently the downstream signaling events due to prolonged EGFR 
autophosphorylation (Hendriks, Wiley, & Lauffenburger, 2003; Li et al., 2012; Waterman et al., 
1998). Signal attenuation is initiated by dephosphorylation via phosphatases, such as density-
enhanced phosphatase-1 (Berset, Hoier, & Hajnal, 2005) and protein tyrosine phosphatase 
PTP1B (Haj et al., 2003).  
1.3.2 EGFR in cancer therapy  
Clinical efficacy often depends on the density of EGFR expressed by cells and the effective 
blockage (Li et al., 2011). The extracellular domain of EGFR is accessible to monoclonal 
antibodies; the binding of these antibodies inhibits the intracellular signal transduction pathways 
that can then respond to angiogenic factors (Harding & Burtness, 2005; Laskin & Sandler, 2004; 
Wieduwilt & Moasser, 2008). Mechanisms of action of anti-EGFR therapeutics include 
physically blocking the ligand from binding (primarily antibodies) or inhibiting the tyrosine 
kinase enzymatic activity (small molecular weight tyrosine kinase inhibitors), which prevents 
autophosphorylation and downstream signaling events. Gefitinib (Iressa®) is a clinically-
approved EGFR tyrosine kinase inhibitor, that has shown to suppress tumour growth at the end 
of a 4-week treatment period of 5 mg/dose in GEO cancer xenografts in immunodeficient mice 
(Ciardiello et al., 2000). Cetuximab (Erbitux®) and panitumumab (Vectibix®) are chimeric 
mouse/human monoclonal antibodies that target the extracellular domain of the EGFR. 
Cetuximab has demonstrated the ability to suppress xenograft tumour growth and has been 
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approved for clinical use against colorectal cancer (Matsuo et al., 2011a; Taniguchi et al., 2018). 
Upon binding of cetuximab, EGFR has been shown to dimerize, but is not accompanied by the 
phosphorylation of downstream proteins, such as Akt and Erk, which are essential in regulation 
of cell proliferation and survival (Matsuo et al., 2011a; Yoshida et al., 2007a). Binding of a 
ligand, such as EGF, will induce a rapid EGF-EGFR complex turnover. The occupation of EGFR 
will be reduced and consequently, interactions with signaling proteins that perpetuate the active 
state of the intracellular signaling pathways will also be reduced (Yoshida et al., 2007b). The 
enzymatic tyrosine kinase function can also be inhibited by low molecular weight molecules that 
compete for the intracellular Mg-ATP binding site to prevent further downstream intracellular 
signalling. Gefitinib (Iressa®) and Erlotinib (Tarceva®) are examples of EGFR tyrosine kinase 
inhibitors used as first-line treatments of advanced non-small cell lung cancer, that can achieve 
prolonged responses to treatment in chemotherapy-naïve patients (Burotto et al. 2015; Giaccone 
et al., 2006).  
1.3.3 HT29 colon adenocarcinoma and EGFR expression 
The colon adenocarcinoma cell line, HT29 (used in this study), expresses relatively high levels 
of EGFR and possesses wildtype KRAS and mutated BRAF (Lewandowska, Jóźwicki, & 
Żurawski, 2013; Van Cutsem et al., 2009). KRAS serves as an effector molecule for signal 
transduction from a ligand-bound EGFR to the nucleus for changes in gene expression; 
mutations in KRAS have displayed persistent downstream signaling without the influence of 
EGFR and high resistance to EGFR-targeted monoclonal antibody therapy (Malumbres & 
Barbacid, 2003). Clinical trial results have revealed that the addition of cetuximab to first-line 
chemotherapy is beneficial to patients with the wildtype KRAS gene (Venook et al., 2017). 
BRAF is a downstream effector of RAS in the EGFR pathway, promoting cell proliferation and 
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survival through the constitutive MAPK signaling pathway (BRAF GENE, 2015). The 
conventional criteria for cetuximab therapy is currently EGFR-positive and KRAS wildtype; 
colorectal cancer patients with the BRAF mutation may be considered to be a minor ‘non-
effective’ group therapy as determined by clinical trials (Laurent-Puig et al., 2009; Van Cutsem 
et al., 2009). BRAF or KRAS mutations decrease the effectiveness of EGFR-targeting 
therapeutics, as the mutations enable constitutive cell proliferation and survival (Wan et al., 
2004; Xu & Solomon, 1996). Therefore, KRAS mutations, and BRAF mutations to a lesser 
degree, typically serve as markers of resistance to anti-EGFR therapy, as patients have shown to 
express a lower response rate than those with wildtype tumours (De Roock et al., 2010; Zhao et 
al., 2017). Mouse HT29 cell xenografts displayed high sensitivity to cetuximab and mitogen-
activated protein kinase (MEK) inhibitor, selumetinib (AZD2644) (Zhang et al., 2018). By 
inhibiting MEK, selumetinib further inhibited extracellular signal-related kinase (ERK) 
phosphorylation and tumour cell proliferation. The combination of  cetuximab reactivated 
MAPK signaling, resulting in the significant inhibition of HT29 cell xenograft growth (Zhang et 
al., 2018).  
One study revealed that EGFR signal transduction was altered by the cetuximab in HT29 cells. 
The level of phosphorylation by growth factors, TGF-α, IGF and EGF, decreased in the presence 
of cetuximab in HT29 cells and partially inhibited the MAPK pathway (Matsuo et al., 2011b). 
Another study by Solmi et al. showed by scanning electron microscopy, significant microvilli 
and filopodia reduction on HT29 cells in response to cetuximab (Solmi et al., 2008). These cells 
lost boundary contacts with other cells as a result, which were indicative of differentiation 
toward apoptosis. Downregulation in MAPK signaling, apoptosis and phosphatidylinositol 
signaling system of HT29 cells was also reported in the same study (Solmi et al., 2008).  
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1.4 3D Cultures 
Clinically, targeting tumour cells without affecting normal cells is a major goal in cancer therapy 
as this would reduce side effects for patients. Low-weight molecules with passive and/or active 
tumour targeting have been investigated for potential clinical applications (Barua & Mitragotri, 
2014; De Jong & Borm, 2008; Kibria et al., 2013; Torchilin, 2005). In vitro cell cultures provide 
a highly controlled environment;  3D tissue models, such as cells grown on structured scaffolds, 
multicellular layers and multicellular tumour spheroids, have been particularly useful in studying 
drug and nanoparticle penetration in vitro as they provide better representation of the complexity 
and state of cancer cells in their native environment (Mikhail, Eetezadi, & Allen, 2013). While 
conventional monolayer cultures may be a convenient and an effective way for predicting 
molecular targets and pathways, they are unable to completely recapitulate the complexity and 
heterogeneity of tumours (Mikhail et al., 2013). Previous studies have shown that while certain 
apoptosis-inducing drugs were effective against monolayer cell cultures, they failed to achieve 
the same level of cytotoxicity in 3D cultures, which may be analogous to the chemoresistance 
often observed in vivo (Barbone et al., 2008; Desoize & Jardillier, 2000; Vermeulen et al., 2008).  
1.4.1 Multicellular spheroids 
Multicellular tumor spheroids (MCTS) serve to bridge the gap between monolayer cultures and 
animal models by effectively mimicking the pathophysiological environment and morphology of 
in vivo solid tumours and demonstrating similar responses to therapy (Zanoni et al., 2016). They 
are preclinical models that re-establish the complex network of cells, ECM, gene expression, cell 
signals, gradients of pH, oxygen, metabolism and proliferation found in solid tumours (Däster et 
al., 2017). The cells in MCTS are concentrically-arranged whereby the outer region is comprised 
of proliferating cells that are abundantly exposed to nutrients and oxygen (Fig. 2). These cells 
15 
 
surround quiescent cells, closer to what is a necrotic core if the MCTS beyond a critical size of 
500 um in diameter (Däster et al., 2017). These characteristics of spheroids ultimately influence 
protein expression, binding and penetration of drugs through the MCTS (Sriraman et al., 2014). 
Some molecular targets also become upregulated, which have previously been exploited for 
selective targeting (Barbone et al., 2008; Howes et al., 2007; Mueller-Klieser, 1997; Wolfgang 
Mueller-Klieser, 1987).  
 
Figure 2: A schematic diagram of a multicellular spheroid. Cells in the outer region are 
rapidly proliferating due to an abundance of oxygen and nutrients. Inner cells are less 
metabolically-active due to decreases in oxygen and nutrients. This leads to the formation of a 
necrotic core in larger spheroids, whereby the lack of oxygen and nutrients leads to cell death.  
One study showed that anticancer drugs, melphalan, irinotecan, oxaliplatin and fluorouracil (5-
FU), were highly active in HCT116 monolayer cultures, but 6-day-old spheroids were almost 
completely resistant (Karlsson et al., 2012). These effects were suggested to have been caused by 
the suppression of genes implicated in DNA replication and cell cycle associated with the 3D 
culture (Karlsson et al., 2012).   
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A population of cells in spheroid culture will display stronger resistance to drugs even in the 
absence of intervening physical barriers (e.g. ECM components), as some cells will be required 
to be in proliferative state for the drug to induce toxicity (Kolonin et al., 2006; Mikhail et al., 
2013). For example, one group treated A549 spheroids with paclitaxel, a microtubule-targeting 
drug that disrupts cell adhesion, to increase the interstitial spaces between cells to achieve equal 
access of cells by a chemotherapeutic drug. This was confirmed by observing the effective 
penetration of 10,000 Da dextrans through spheroids (Russell et al., 2017). Despite the increased 
accessibility of cells for the chemotherapeutic drug pemetrexed, a population of cells remained 
unperturbed and viable. 3D cultures reproduce the metabolic gradients and altered cell-cell 
contacts that are more representative of in vivo solid tumours; therefore, MCTS are considered to 
be more reliable in predicting a drug’s therapeutic potential than conventional monolayer 
cultures in preclinical studies (Eriksson et al., 2009; Friedrich et al., 2009a).   
Spheroids can be monitored for their change in size and morphology in response to a drug by 
standard phase-contrast microscopy, while the measurement of drug penetration can be 
accomplished by confocal microscopy (Bryce et al., 2009b; Mehta et al., 2012; Mittler et al., 
2017; Svishchev & Goncharov, 1990; Vermeulen et al., 2008; Ying et al., 2010; Zanoni et al., 
2016). Typically, spheroids with diameters of up to 300 µm are employed in drug testing, which 
exhibit well-developed cell-cell, cell-matrix interactions and reproducible results in drug 
screening (Enmon et al., 2003; Friedrich et al., 2009a; Moran et al., 2012; Rubin, Voronkov, & 
Zhivopistseva, 1975). Although the use of larger spheroids is tempting to model the behaviour 
and characteristics of solid tumours and their response to treatments, it is difficult to achieve 
reproducible results. Zanoni et al. demonstrated that the variability of parameters, such as 
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volume, shape and sphericity caused spheroids to display different responses to treatments – all 
of which were amplified by larger spheroid size (Zanoni et al., 2016).   
1.4.2 Parameters affecting drug penetration into solid tumours 
Physical properties of molecules such as particle size, shape, charge, and hydrophobicity can 
influence the passive transit through intercellular spaces of solid tumours (Aggarwal et al., 
2009). Delivery agents are also affected by contact with the ECM and cell surface. Numerous 
drug delivery technologies have been developed as carrier systems for therapeutically active 
agents, including liposomes (Torchilin, 2005), micelles (Kataoka, Harada, & Nagasaki, 2012), 
antibodies (Walker et al., 1988), affinity targeting and macromolecular drug carriers (Dreher et 
al., 2006a). However, these particles were found to be restricted to the tumour vasculature with 
very little infiltration due to their sizes (Grill et al., 2002). Adenoviral gene transfer in spheroids 
has also been assessed but poor penetration was observed despite the application of high titers of 
1010 PFU/spheroid; transfection was observed only occurring in the first two cell layers of the 
spheroid (Grill et al., 2002).  
All nanoparticles move more slowly through the fluid than conventional therapeutic agents, as 
process of diffusion is much more efficient for smaller particles (Florence, 2012; Huang et al., 
2017). However, larger particles can benefit from the enhanced permeability and retention effect 
(EPR). The rate of clearance in the tumour tissue is reduced due to the poor lymphatic system, 
which can facilitate the selective accumulation and retention of larger nanoparticles. Small 
molecules, however, can manage to escape the tumour vessels through the fenestrations (Khawar 
et al., 2015). Dreher et al. studied the depth of penetration of dextrans with sizes ranging from 
3.3 kDa to 2 MDa. After 30 min, maximal accumulation in the tumour was observed for dextrans 
40 – 70 kDa (diameters of 11.2 – 14.6 nm), approximately 15 μm from the vessel wall (Dreher et 
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al., 2006a). This was due to the increased accumulation of these molecules, whereas their lower 
molecular weight counterparts were subjected to a higher rate of clearance (Dreher et al., 2006a). 
Passive tumour targeting by nanoparticles relies primarily on EPR, which can enhance their 
accumulation in tumour tissues more than in healthy tissues (Maeda, Tsukigawa, & Fang, 2016).  
Neutral and positive surface charges contribute to diffusion of nanoparticles into spheroids 
(Kostarelos et al., 2004). Negatively-charged quantum dots were able to penetrate deeply into 
HeLa spheroids, contrary to their positively-charged counterparts that were confined to the rim 
(Ma et al., 2012). The shallow depth of penetration by cationic liposomes was suggested to have 
been caused by the electrostatic binding between the positive liposomes and negatively-charged 
surface of cells, inhibiting further diffusion (Lee et al., 2002). Surface coating, such as by PEG, 
can reduce these electrostatic interactions of nanoparticles with cells and assist in evasion from 
the reticuloendothelial system (RES). However, depth of penetration can be compromised due to 
the increase in overall size (Kostarelos et al., 2004). Finally, the shape of the nanoparticle also 
determines its diffusivity. Although conventional carrier systems are spherical, rods or 
filamentous shapes may be more optimal. They have shown to diffuse more rapidly into 
spheroids with greater accumulation in vivo and in vitro (Chauhan et al., 2011; Decuzzi et al., 
2010; Lee et al., 2013; Lee, Ferrari, & Decuzzi, 2009). Nanorods and nanospheres with the same 
hydrodynamic diameter of 33 nm were compared for transport across porous membranes in vitro. 
Nanorods were able to diffuse 5.3 times deeper than nanospheres through 100-400 nm collagen 
gel pores, which are approximate pore sizes of tumour vascular walls (Chauhan et al., 2011).  
Fusion of molecules to enhance cellular uptake and penetration has been widely investigated. 
These molecules include tumour-homing and cell-penetrating peptides, such as arginine-glycine-
aspartic acid (RGD) (Shi et al., 2015), TAT (Zong et al., 2014), and MPG (Sims et al., 2016). 
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The fusion of RGD to lipid coated nanoparticles significantly improved its biodistribution in 
spheroids of C6 glioblastoma cells that overexpress integrin α(v)β3 in vitro (Shi et al., 2015). 
iRGD is a 9-amino acid, cyclic tumour-penetrating peptide with greater binding affinity than the 
standard RGD motif (Sugahara et al., 2015). The co-administration of iRGD significantly 
improved the extravasation of nanoparticles from the tumour vessels into the glioma 
parenchyma, resulting in overall greater accumulation in nude mice (Gu et al., 2013). Another 
group designed liposomal systems modified with TAT and T7 to enhance penetration into the 
glioma the blood-brain barrier, respectively (Zong et al., 2014). TAT-liposomes showed deeper 
penetration into the C6 tumour spheroids in vitro than T7-liposomes, but the opposite was 
observed in vivo. This was probably caused by the nonselectivity of TAT, as well as interference 
of natural diffusivity by the liposomes (Zong et al., 2014). Having both molecules fused to 
liposomes resulted in the highest accumulation in the glioma due to synergistic effects (Zong et 
al., 2014). The ability of nanoparticles to diffuse through the spheroid does not always correlate 
to their total accumulation in the spheroid. The conjugation of MPG, synthetic peptide derived 
from HIV gp41 and SV40, increased uptake of nanoparticles in HeLa spheroids by almost three-
fold. PEG-nanoparticles, however, were localized mainly in the spheroid periphery, but were 
able to penetrate tissue culture by almost two-folds further than the MPG-nanoparticles (Sims et 
al., 2016). 
In vitro modeling of nanoparticle penetration into spheroids is also affected by external 
parameters such as temperature and cell type. The penetration efficiency is reduced at lower 
temperatures as modeled by the equation for Brownian motion. At higher temperatures, the 
viscosity of the liquid medium decreases, resulting in faster diffusion of nanoparticles (Florence, 
2012). Cell type will affect in variations in packing density and intercellular channel sizes, 
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influencing the overall kinetics of the particle. Certain cells form larger interstitial spaces 
enabling nanoparticle movement, which does not necessarily reflect the penetrability of the 
nanoparticle itself. Stromal spheroids will appropriately model the structural barrier that restrict 
particle movement in vivo (Friedrich et al., 2009a; Priwitaningrum et al., 2016). Mikhail et al. 
reported that despite the treatment of HT29 and HeLa spheroids with the same concentration of 
docetaxel, different responses were observed; HT29 spheroids consist of more non-proliferating 
cells with higher packing density than HeLa spheroids (Mikhail et al., 2013). Therefore, it is 
crucial to screen therapeutic molecules in spheroids generated from various cell types to 
appropriately assess their kinetic properties.  
1.5 Bacteriophages   
Bacteriophages (phages) are viruses that exclusively infect bacteria, and like plant and animal 
viruses, phages are unable to propagate in the absence of a host. The bacterial host provides 
machinery and organic material for phage biosynthesis and packaging (Clokie et al., 2011). 
Phages are the most abundant biological entities on earth – an estimate of 1031 particles exist as 
free virions or within their bacterial hosts (Ashelford et al., 2000). All phages undergo the 
general process of adsorption to their bacterial host(s), DNA injection, replication, virion 
production, followed by release (Clokie et al., 2011).  
The human body is extensively colonized by phages, and the ubiquitous nature of phages leads to 
constant exposure to a diverse spectrum of phages from birth. Phages colonize the skin (Oh et 
al., 2016), lungs (Dickson & Huffnagle, 2015), oral cavity (Pride et al., 2012), gut (Reyes et al., 
2010), and urinary tract (Santiago-Rodriguez et al., 2015), contributing to an extensive genetic 
diversity to humans, and ultimately playing an essential role in maintaining our health (Abeles & 
Pride, 2014). The gut microbiota consists mainly of phages, with an estimate of 109 virus-like 
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particles per gram of stool (Kim, 2011). In healthy humans, this includes double-stranded DNA 
viruses of the Podoviridae, Siphoviridae and Myoviridae family (Breitbart & Rohwer, 2005; 
Reyes et al., 2010). The diversity of phages contributes significantly to the gut microbiota 
structure and function. Phages may serve as reservoirs of genetic diversity by serving as vehicles 
for horizontal transfer of virulence and antibiotic resistance for their bacterial host (Nadeem & 
Lindi Wahl, 2016). Additionally, these entities may play a role in the defense of the mucosal 
barrier against bacteria. The Ig-like domains exposed on the surface of phages have been shown 
to interact with the mucin glycoproteins to decrease bacterial colonization of the mucosa, thereby 
reducing bacterial translocation and the potential for bacteremia (Barr et al., 2013a).  
Phages have received enormous amount of attention in the last decade for its potential 
applications. This includes treatment of bacterial infections as well as its potential for genetic 
therapy (Bakhshinejad, Karimi, & Sadeghizadeh, 2014; Donnelly et al, 2015; Hosseinidoust, 
2017). Phages have no natural tropism for mammalian cells as they would for bacterial hosts and 
have resided in our bodies throughout hominid evolution in a tripartite relationship with their 
bacterial and human hosts (Clokie et al., 2011). For decades, phages have extensively been used 
in Eastern Europe for treatment of bacterial infections, but have only recently garnered interest 
for their influence of cancer processes (Abedon et al., 2011; Kaur et al., 2012). Phages have 
demonstrated intrinsic antitumour activities such as slowing the tumour growth (Bloch, 1940; 
Dabrowska et al., 2007; Eriksson et al., 2009; Górski et al., 2015; Huh et al., 2019; Ivanenkov & 
Menon, 2000; Rangel et al., 2013). The most widely known example of this is perhaps the 
attachment of T4 phages to B16 melanoma cells mediated by the Lys-Gly-Asp (KGD) motifs 
present on the phage capsid with the integrin β1 and β3 integrin receptors on target cancer cells. 
This resulted in decreased tumour metastasis (discussed in Chapter 1.5.4) (Dabrowska et al., 
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2004). Administered phages have also shown remarkable penetrative capabilities through various 
cell types, passing through relatively impermeable physiological barriers in our bodies. This 
includes the blood-brain-barrier, which often restricts the movement of molecules that are less 
than 500 Da, lipophilic, and share a structural homology to compounds that enter the brain 
through active transport (Abbott, Rönnbäck, & Hansson, 2006; Huh et al., 2019; Pardridge, 
2003). Intraperitoneal (Dubos, Straus, & Pierce, 1943) and intranasal (Solomon, 2008) 
application of M13 phages in mice have resulted in their recovery in the brain as early as 1 h 
following administration. Phages can also cross the gut mucosal barrier as orally administered 
phages have been recovered in the blood of mice (Majewska et al., 2015; Miȩdzybrodzki et al., 
2017). Administered phages can bypass the gut flora, adhere to the glycoproteins in the mucosa 
and traverse the epithelium transcellularly or via M cells (Barr et al., 2013b; Huh et al., 2019). 
Recently, the mechanism for transcytosis across epithelial cells have been described by Nguyen 
et al. Transcytosis was observed for 0.1% of applied phages in the apical-to-basal direction. 
Phages applied topically to clear bacterial infections have shown to penetrate through the 
multiple layers of the skin, from the epidermis to the adipose tissues (Kumari, Harjai, & 
Chhibber, 2011). Soothill et al. excised and replaced skin grafts extending down to the 
subcutaneous fat, but the topical application of phages prevented the graft destruction by 
Pseudomonas aeruginosa, demonstrating the ability of phages to permeate the skin tissue 
(Soothill, 1994). This unique ability of phages to pass through minute intercellular spaces may 
lead to effective extravasation, infiltration and accumulation in the tumour microenvironment, 
possibly representing a huge potential for a drug delivery platform for phages in cancer therapy.   
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1.5.1 Phage internalization and cellular trafficking in eukaryotic cells 
Despite the ubiquity of phages in the environment, our knowledge of phage interactions with 
mammalian cells is very limited. There is evidence that phages can bind to the surface and be 
internalized by eukaryotic cells, but the penetration of phage DNA into the nucleus, replication 
and release of progeny particles have not been directly observed. Over 40 years ago, lambda 
phage transduction in human fibroblasts was demonstrated by Merril et al. Cells infected with 
phages harboured about 0.2% of cellular RNA that was λ-specific (lambdoid phage-encoded β-
galactosidase) (Geier & Merril, 1972). Since then, targeted phage transduction in mammalian 
cells have been extensively studied by measuring the expression of GFP, neomycin 
phosphotransferase or β-galactosidase (Kassner et al., 1999; Larocca et al., 2001; Larocca et al., 
2008; Poul & Marks, 1999). Phage display (Chapter 1.5.2) can be used to fuse targeting ligands 
on the phage surface; this combined with a mammalian expression cassette can confer 
mammalian tropism for the phage (Baird, 2011). The interactions between targeting ligands and 
their cognate receptors increase the likelihood of phage-internalization in a concentration-
dependent manner, and subsequently their transfection efficiency (Aalto et al., 2001; Dabrowska, 
et al., 2005; Kassner et al., 1999; Larocca & Baird, 2001; Lehti et al., 2017; Poul & Marks, 
1999). Kassner et al. demonstrated that M13 filamentous phages displaying EGF peptides were 
able to transduce COS-1 cells by delivering a GFP gene. Transduction efficiency was shown to 
be greater by 100-fold than by control phages without any display (Kassner et al., 1999). 
Transduction was observed with concentrations as low as 250 phage particles/cell and increased 
in a dose-dependent manner. This ligand density-dependent increase in transduction efficiency 
has also been shown with the display of fibroblast growth factor (FGF2) (Kassner et al., 1999) 
and scFv antibody fragment (Poul & Marks, 1999), targeting the fibroblast growth factor 
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receptor and ErbB2 receptor, respectively. The display of RGD peptides by filamentous phages 
has also mediated cell internalization via multivalent binding to integrin receptors in vitro. 
Phages were internalized in less than 15 min, in a process resembling phagocytosis more than 
receptor-mediated endocytosis. Packaging into clathrin-coated vesicles require particles to be 
less than 100-150 nm in diameter, but filamentous phages are often between 800–2000 nm in 
length (Lamaze & Schmid, 1995).  
Phage internalization is not contingent on phage surface modifications to display cell-targeting 
ligands. Recently, Lehti et al. demonstrated the ability of E. coli phage PK1A2 to bind 
specifically to polysialic acid receptors on eukaryotic neuroblastoma cells in vitro, without the 
mediation of phage surface modifications (Lehti et al., 2017). Furthermore, there was strong 
evidence that this induced internalization of the phage-polysialic acid complex; fluorescent 
phages appeared intracellularly as early as 30 min after incubation and increased up to 24 h. 
Polysialic acid bears structural similarity to a bacterial receptor that mediates phage entry (Petter 
& Vimr, 1993). It has been postulated by the authors that there are other undiscovered surface 
epitopes on eukaryotic cells that can be bound specifically by phages, due to an abundance of 
structurally-similar carbohydrates shared between pathogenic bacteria and host eukaryotic cells. 
Following cellular uptake, phages are likely directed to the endolysosomal pathway, losing 
infectivity in the lysosomes (Ivanenkov, Felici, & Menon, 1999; Lehti et al., 2017). 
1.5.2 Phage display 
Although wildtype T4 phages without any surface modifications have demonstrated antitumour 
activities (see 1.5.4) (Bloch, 1940; Dabrowska et al., 2007; Eriksson et al., 2009; Górski et al., 
2015; Huh et al., 2019; Ivanenkov & Menon, 2000; Rangel et al., 2013), phages can be 
engineered to enhance their application and efficacy profile. Tropism for specific cells can be 
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conferred by fusing cell-targeting ligands to surface proteins (Beghetto & Gargano, 2011). This 
is known as phage display technology, whereby a peptide or protein coding gene is 
translationally fused to the capsid gene of the phage. As a result, the phage product will carry the 
gene for the protein/peptide of interest and will be capable of replication within the construct 
(Kaur et al., 2012). This approach has been extremely powerful in isolating ligands for drug 
discovery, identifying protein-protein interactions and antibody fragments, epitope mapping, as 
well as phage engineering for specific targeting of tissues and cells (Nicastro et al., 2016). 
Peptides with desired binding profiles can be selected for in a process called “biopanning,” 
which has further progressed to live animal ‘in vivo panning’ (Pasqualini & Ruoslahti, 1996). 
This approach has since been extensively investigated in cancer therapy; tumour-specific ligands 
have been screened and isolated by their affinity and specificity to neoplastic cells and vascular 
endothelium (Pasqualini & Ruoslahti, 1996; Poul et al., 2000). While monoclonal antibodies can 
also achieve high affinity and specificity, their large size is a limiting factor for effective 
penetration into the tumour tissue (Scott, Wolchok, & Old, 2012).  
Much success has been achieved by utilizing isolated peptides from screening phage display 
libraries for delivery of nanoparticles to tumours (Krumpe & Mori, 2006). Several peptides have 
been identified to bind to HER2 (Urbanelli et al., 2001), EGFR (Karasseva et al., 2002), IL-6 
receptor (Su et al., 2005). Furthermore, peptides isolated from phage-display peptide libraries 
have progressed to phase III clinical trials, such as Amgen’s AMG-386, an anti-angiogenic 
therapeutic for treatment of various cancers, and Romiplostim (AMG 531), drug approved by the 
FDA for the treatment of thrombocytopenia (Jamali et al., 2009; Shimamoto et al., 2012).   
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1.5.3 Tuneable λ phage display 
Bacteriophage λ is a temperate phage in the family of Siphoviridae viruses, with icosahedral 
capsid (~50 nm in diameter), long fibrous tail (150 nm in length) and double-stranded genome 
(~48 kb) (Geier & Merril, 1972). The capsid consists of two major coat proteins, gpE and gpD, 
which are responsible for the structure of the prohead and stability during genome packaging, 
respectively (Fig. 3). gpD consists of 109 amino acids and cuts the concatemers at the cohesive 
end site (cos) during packaging of the DNA into the phage prohead while simultaneously 
stabilizing it. gpD-deficient mutants result in 82% of the DNA content of wildtype λ phage 
(Sternberg & Weisberg, 1977). Phage λ is able to carry large DNA fragments, has high 
infectivity and offers several advantages over filamentous phages (Lankes et al., 2007; Piersanti 
et al., 2004; Sternberg & Hoess, 1995). It is similar in size and shape to mammalian viruses, has 
double-stranded DNA genome, and despite its small size, the mature λ-head can package large 
amounts of DNA fragments of up to 50 kb (Beghetto & Gargano, 2011; Mikawa, Maruyama, & 
Brenner, 1996; Razazan et al., 2019; Sternberg & Hoess, 1995). It can also accommodate larger 
exogenous proteins with a high copy number, conferring high avidity for a target receptor 
(Piersanti et al., 2004). Phage λ can be employed for phage display via both gpD, and the tail 
protein, gpV (Mikawa et al., 1996; Santini et al., 1998; Sternberg & Hoess, 1995). There are 415 
copies of gpE and 405 – 420 copies of gpD (Beghetto & Gargano, 2011). It was reported by 
Piersanti et al. that phage λ possessed a more efficient display system compared to filamentous 




Figure 3: A schematic diagram of bacteriophage λ and one face of the capsid. The capsid 
head is composed of gpD and gpE proteins incorporated into trimers and hexamers, respectively. 
λ icosahedral head comprises a total of 20 faces and 405-420 of each gpD and gpE proteins 
(image adapted from Nicastro 2013).  
1.5.4 Phages and cancer 
Anticancer properties of T4 phages have been reported, demonstrated by the inhibition of lung 
metastasis of B16 melanoma cells by the binding of T4 and its sub-strain HAP1, mediated 
through the KGD motif on the gp24 phage capsid protein and to the cell surface β3 integrins 
(Dabrowska et al., 2004; Dabrowska et al., 2004, 2007). Certain animal viruses, such as 
adenovirus, HIV, HPEV1 virus and hantavirus, use integrins for cell entry, which are present on 
platelets, monocytes and some neoplastic cells (Gavrilovskaya et al., 1999; Lafrenie et al., 2002). 
The blockade of integrins downregulates its functions, which has been postulated to be the cause 
of anti-metastatic activity imparted by these phages (Gorski et al., 2003). Phages in the context 
of cancer immunotherapy has also been of interest, as Eriksson et al. described the phage-
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induced tumour regression in mice (Eriksson et al., 2009). Administration of tumour-specific 
phages secreted proinflammatory cytokines IL-12 and interferon γ, resulting in the migration of 
mouse neutrophils to the site of tumour and potentiating tumour destruction (Eriksson et al., 
2009). Arab et al. also studied the immunogenicity of λ phage particles displaying E75 peptide 
derived from HER2/neu in a TUBO cell xenograft model of BALB/c mice (Arab et al., 2018). 
This resulted in the induction of CD8+T cells for mice that were vaccinated with the phages with 
significantly reduced the size of the tumour.  
1.5.5 Immune response to phage therapy  
Immune response to phage administration can be influenced by: i) the size and number of surface 
epitopes; ii) route of administration; iii) dose and frequency of phage administration and iv) 
patient history of exposure (Kaur et al., 2012). Antibodies against naturally-occurring phages, 
such as T4, are detected in the sera of humans. In one study, 50 healthy humans were tested for 
phage antibodies, of whom 81% were found to possess IgG antibodies against the T4 capsid 
proteins – gp23, gp24 and Soc. This was most likely a result of natural contact with phages in the 
environment (Dąbrowska et al., 2014).  
Oral phage administration has typically shown weak immune responses in humans, with only 
marginal changes in serum anti-phage antibodies (Bruttin & Brüssow, 2005). Intravenous 
injection of phages, however, result in the rapid phage clearance from the reticuloendothelial 
system (RES) (Clark, 2015; Merril, Scholl, & Adhya, 2003). The RES is comprised of 
phagocytic cells that reside in the lymph nodes and the spleen, including Kupffer cells 
(specialized mononuclear phagocytes) of the liver. These cells remove foreign phage particles, 
posing a significant challenge to the maintenance of applied phage titers in vivo (Hodyra-
Stefaniak et al., 2015). As a result, significant titers of phages have been recovered from the 
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spleen in mice, regardless of the route of administration (Gieir, Trigg & Merril, 1973). The half-
life of phages in circulation often depend on phage surface protein sequences; Merril et al. 
showed the ability to select for mutant λ phages that were able to persist in circulation for several 
hours by effectively evading Kupffer cells in mice (Geier et al., 1973; Merril et al., 1996) 61].  
There have been reports of both pro- and anti-inflammatory cytokine release in response to 
phages. Weber-Dabrowska et al. studied the effects of phages on the tumour necrosis factor-α 
(TNF- α) and interleukin 6 (IL-6) levels in the sera of 51 patients with suppurative infections 
(Weber-Dabrowska, Zimecki, & Mulczyk, 2000). Long-term treatment with phages led to 
elevated levels of these cytokines; however, like many other similar studies testing cytokine 
levels in response to phage therapy, it is unclear whether the short-term normalization or 
reduction in the proinflammatory cytokine levels were influenced by the reduced burden of 
pathogenic bacteria in the body. A different study monitored changes of 12 proinflammatory 
cytokines including IL1, IL2, IL10, IL17, IFN-γ and TNF- α in response to orally fed T7 phage 
in mice, and only IL17A was slightly elevated (less than 10%) compared to the control group 
that was fed SM buffer (Park, Cha, & Myung, 2014). Histopathological analysis of the same 
study showed no noticeable differences in the tissue samples of the gastrointestinal tract. Anti-
inflammatory action of phages has also been reported; a study used highly purified 
Staphylococcus aureus and Pseudomonas aeruginosa phages to stimulate peripheral blood 
mononuclear cells (PBMCs) derived from healthy human donors. The genes for IL1RN (an anti-
inflammatory IL1 receptor antagonist) and SOCS3 (suppressor of cytokine signaling 3) were 
upregulated, while proinflammatory cytokines such as IL1A and IL1B, were also elevated. 
Therefore, phages appear to activate several immunological pathways following administration 
(Van Belleghem et al., 2019).  
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1.5.6 Phage penetration of solid tumours  
The ability of phages to penetrate through the various regions of solid tumours may depend on 
several factors including the size and morphology of the phage, surface charge of the phage, 
interactions with the ECM, and the potential binding and internalization to the eukaryotic cells. 
Diffusing particles often interact with molecules during their transit through intercellular spaces, 
although outcomes will vary significantly depending on whether the interaction is specific or 
non-specific (Florence, 2012). Specific interactions, such as those of monoclonal antibodies and 
tumour antigens, can impair tumour penetration by binding to external cells, resulting in poor 
biodistribution in the solid tumour in what is known as the “binding site barrier” (Adams et al., 
2001; Juweid et al., 1992). This effect is often dependent on the binding affinity and antigen 
density, and is often the cause of poor nanoparticle diffusion and unintended internalization by 
stroma cells near the blood vessels (Juweid et al., 1992; Miao et al., 2016).  
Recently, E. coli phage lysate enriched from sewage has been reported to bind to three major 
macromolecules of the ECM– gelatin (denatured collagen), fibronectin, and heparin by column-
based assays (Porayath et al., 2018). ECM biochemically impedes vector access to tumour cells 
(Netti et al., 2000). The same phage lysate was used to test their ability to protect HT29 cells 
against infection by pathogenic host bacteria. Phage adherence to HT29 cells was evidenced, as 
phages were able to reduce the bacterial load by 48%, even after washing of the cells to discard 
unbound phages. These phages did not show signs of cytotoxic effects on HT29 cells by the 
Resazurin assay.  
Adeno-associated virus/phage (AAVP) is a hybrid phage vector with a mammalian transgene 
cassette harbouring inverted terminal repeats from adeno-associated virus 2 as well as a peptide 
display vector from fd phage genome. The AAVP displays iRGD that enables homing and entry 
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to αv integrin receptors and has been used widely for gene delivery into cancer cells (Hajitou et 
al., 2007; Przystal et al., 2013; Smith et al., 2017). A study by Yata et al. showed that despite the 
narrow shape (6.5 nm x 1400 nm) of AAVP, diffusion through the ECM-gel matrix was still very 
poor. Infiltration, internalization and gene expression were significantly improved after the 
depletion of ECM constituents with collagenase and hyaluronidase (Yata et al., 2015). 
Bacteriophage penetration through a MCTS has not been clearly characterized but remains to be 














Chapter 2: Rationale, Objectives and Hypothesis 
2.1 Rationale  
A prominent problem with cancer gene therapy is the incomplete eradication of tumors, which 
frequently results in the recurrence of cancer. Bacteriophages have naturally demonstrated the 
ability to bind to the surface of mammalian cells as well as the capacity to penetrate different cell 
type layers and various physiological barriers in the human body. Phages may be able to 
overcome physical barriers commonly presented in solid tumour drug delivery, including high 
packing density of constituent cells and the high interstitial fluid pressure. Therefore, we sought 
to understand whether unmodified bacteriophage λ can passively target and diffuse within 
multicellular spheroids generated from NIH3T3 mouse fibroblasts. Fibroblasts are stromal cells 
that secrete connective tissue components, hindering drug penetration into solid tumours. Phage 
λ was selected for its ability to tolerate larger and higher density of protein fusions without 
compromising phage assembly. Additionally, the dual-control display system to variably 
decorate the surface of phage λ has previously been investigated in our lab.  
The display of peptides to the surface of phages can enhance specific targeting of phages to cells 
and tissues. We chose EGF for peptide of display for phage λ, as it has been successfully used 
for targeting of other types of vectors in several gene therapy applications to date (Kassner et al., 
1999; Larocca, Burg, & Baird, 2005). EGFR blockade has also been implicated in slowing of 
tumorigenesis and cancer progression (Harding & Burtness, 2005; Matsuo et al., 2011a; Scaltriti 
& Baselga, 2006). HT29 colon adenocarcinoma cells were selected for spheroid culture, which 
expresses high EGFR levels. The multivalent EGFR display on phages would likely enhance 
their accumulation in HT29 spheroids. Through this exploratory research, a greater 




Bacteriophage Lambda (λ) can interact with multicellular spheroids generated from colorectal 
adenocarcinoma HT29 cells and mouse fibroblast NIH3T3 cells. The display of EGF on lambda 
phage will further enhance binding, uptake and accumulation into spheroids. The specific 
binding to EGF receptors on cells can thereby slow spheroid formation and growth.   
2.3 Objectives 
The main objective of this research was to assess the phage-mammalian cell interactions in the 
context of 3D multicellular spheroid cell culture. Specific objectives were:  
1. To visualize the intrinsic capacity of fluorescent phage λ to adhere and accumulate in 
HT29 and NIH3T3 multicellular spheroids.  
2. To assess the impact of phage λ on HT29 spheroid formation and growth.  
3. To measure the internalization of phage λ into HT29 cells in spheroids.  
4. To assess cytotoxicity induced by phage λ in HT29 monolayer cells and spheroids.  







Chapter 3: Materials and Methods 
3.1 Buffers and solutions 
Ampicillin Stock (Sigma Aldrich, Oakville, Canada)  
This was used as a selective marker for the pPL451 plasmids in the E. coli hosts and was added 
to broth at 100 μg/ml from a stock prepared at a concentration of 50 mg/ml into filter-sterile 
water. This stock powder was stored at -20 °C.  
Luria Bertani Broth  
LB broth is a nutritionally-rich medium used for the rapid propagation of bacteria in culture. It 
consists of 10 g tryptone, 5 g yeast abstract and 5 g NaCl dissolved in 1 L MilliQ H2O, sterilized 
(autoclave) and stored at room temperature.   
LB Agar 
LB agar was used as a solid support for the growth of bacterial cultures. It consists of 10 g 
tryptone, 5 g yeast abstract, 5 g NaCl and 13g Grade A Bacto™ agar (Difco Laboratories) 
dissolved in 1 L MilliQ H2O. It was sterilized, poured onto sterile plates and stored at 4 °C.  
LB Top Agar 
LB top agar was used as an overlay on top of regular nutrient agar plates. The semi-solid 
consistency permits progeny phages to diffuse through the media to infect the evenly-dispersed, 
“lawn” of bacterial culture. It consists of 10 g tryptone, 5 g yeast abstract, 5 g NaCl and 7 g 
Grade A Bacto™ agar, dissolved in 1 L MilliQ H2O, sterilized and stored in 52 °C water bath to 





PEG (Polyethylene Glycol)  
PEG was used to precipitate phage particles and purification. It was prepared by dissolving 0.2 
M PEG 8000, 0.15 M NaCl in 1 L MilliQ H2O (pH 7.8), filter-sterilized and stored at room 
temperature.  
TN Buffer  
Phages were stored in TN buffer at 4 °C. It was prepared by dissolving 0.1 M NaCl, 0.01 M Tris-
HCl (pH 7.8) and autoclaving afterwards. This was stored at room temperature.  
TN/EDTA Buffer  
This buffer was used to test for phage sensitivity. 0.1 M NaCl, 0.01 M Tris-HCl, 0.1 M EDTA 
was dissolved in 1L MilliQ H2O (pH 7.8). This was sterilized and stored at room temperature.  
PBS 
PBS was used to perform washes of spheroids to rid of unbound phages and dyes. It was 
prepared by dissolving 1370 mM NaCl, 27mM KCl,100mM of Na2HPO4, 18mM of KH2PO4 in 










3.2 Bacterial and bacteriophage strains, plasmids and eukaryotic cells 
Table 1: Summary of bacteria, phage, plasmids and eukaryotic cells used in this study  
Cell Genotype Source/Reference Additional Information 





Agilent Technologies, Inc. This strain encodes a double 
suppression action (SupE and SupF) 
and serves as the positive control for 
the efficiency of plating (EOP) of 
F7 samples.   
 
W3101  F-, galT22, λ-, 
IN(rrnD-rrnE)1, 
rph-1, 
CGSC #4467  Bachmann (1972)  This strain does not exert any amber 
suppression action and serves as the 
negative control for F7 samples as 
F7 is not viable on this host. 
W3101 
SupD 





Nicastro et al. (2013) Amber isogenic suppressor SupD 









Nicastro et a. (2013) Amber isogenic suppressor  SupF 
strains of W3101. W3101 SupF 
(tyrT5888) 
Phage Strains  
λF7 λDam15imm21cI
ts 
Mikawa et al. (1996) Maruyama et al. 
(1994) 
λ phage harbouring an amber 
mutation in the gene encoding gpD, 
and is able to form viable particles 
in the presence of the amber (UAG) 
stop codon at the position 68 of the 
110 amino acid protein.   
 









Sokolenko et al. (2012), Nicastro et al. 
(2013) 
Multicopy plasmid pPL451 that is 
under the control of a temperature-
sensitive allele of the λ CI857 
repressor. The EGF sequence is 
fused to the C-terminal of the gpD 
capsid gene that is separated by an 
in-frame linked sequence 
p(TSGSGSGSGSGT) and a KpnI 
cut site.  
Eukaryotic Cell Line obtained from the American Type Culture Collection (ATCC®) 
NIH3T3 Mouse fibroblast cells 
HT29 Human colorectal adenocarcinoma 
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3.2 Cell culture 
Cell lines were obtained from the American Type Culture Collection (ATCC®) and were 
maintained in T25 flasks at 37 ᵒC in a humidified atmosphere of 95% air and 10% CO2. Cells 
were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Thermo Scientific) 
supplemented with 5% heat-inactivated foetal bovine serum (FBS). The culture medium was 
replaced every 3 d.  
3.3 Spheroid culture 
The characteristics and growth of multicellular spheroids with various seeding densities and cell 
lines were observed and recorded. At 90% confluency, NIH3T3 or HT29 monolayer cells were 
trypsinized (0.25% trypsin-EDTA) into single cell suspensions and were counted with a 
hematocytometer (Fisher Scientific). NIH3T3 fibroblast spheroids were generated at 30,000 cells 
for initial seeding density and were cultured for 10 d. HT29 colon adenocarcinoma spheroids 
were generated by seeding 5, 000 cells and were cultured for 7 d. To examine the spheroid 
growth over time, various seeding densities were imaged every 2 d using a bright-field 
microscope (Nikon® TE200). The spheroid diameters were measured using the QCapture Pro™ 
7 software and Micropublisher 5.0 RTV camera by projecting a bright-field image of the 
spheroid onto the screen and using the calibration wizard for the select objective lens and 
obtaining a measurement by extending the bar over the spheroid.    
Spheroids were generated using 1.5% agarose (weight/volume) in serum-free DMEM and cast in 
a 96-well cell-culture plates. Cells were seeded in 200 µl of DMEM supplemented by 5% FBS 
and incubated at 37 ᵒC and 10% CO2. The growth of each spheroid was recorded for up to 14 d. 
Each spheroid was harvested using a glass pipette and treated with 108 PFU of phage, unless 
otherwise stated.  
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3.4 Phage display  
Phage display of EGF molecules on λ phage particles was achieved by the dual-control 
expression system that using amber mutant D capsid phage, λF7, that imparts a truncated gpD 
protein in a wildtype E. coli host. Through this system, viable progeny particles can be produced 
via amber suppression from suppressor strains of E. coli that possess mutated tRNA that reads 
the UAG stop codon and insert a different residue, allowing the full translation of Dam15 for a 
full length gpD capsid protein. W3101 SupD (serU132) and SupF (tyrT5888) are amber 
suppressor strains of E. coli that form alleles of gpD that is less optimal due to the insertion of 
amino acid serine and tyrosine, respectively, in the place of the UAG stop codon. In contrast, the 
SupE (glnV44) suppressor strain counterpart can fully restore gpD by the replacement of 
glutamine in place of the amber stop codon, fully suppressing the amber mutation. Functional 
gpD alleles can also be provided in trans via complementation using a plasmid [pPL451 
gpD::EGF] encoding a D allele translationally fused to the EGF or other gene of interest, 
resulting in the EGF peptides fused to gpD capsid proteins.  
3.4.1 Transformation 
 [pPL451-gpD::EGF] is a multicopy plasmid that expresses gpD:EGF and is under the control of 
a temperature-sensitive allele of the λ CI857 repressor that induces the gene at temperatures 
above 37 oC, conferring ampicillin resistance to the host (Sokolenko et al., 2012). A C-terminal 
EGF fusion to the capsid protein gpD was designed and constructed. Competent W3101 SupD 
and SupF – amber suppressor E. coli cells – were transformed with [pPL451-gpD::EGF] via heat 
shock and transformed colonies were selected on Luria Bertani (LB) ampicillin agar plates.   
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BB4 (supE, supF) E.coli is the double amber suppressor that results in functional λF7 phage 
particles without the presence of the fusion plasmid; this strain served as a positive control for 
efficiency of plating, and a negative control for EGF decoration (Nicastro et al., 2013). 
Nicastro et al. demonstrated that maximal decoration  of λF7 is conferred by generating phages 
at higher temperatures (37 ᵒC), using SupD E.coli amber suppressor host for propagation 
(denoted as ‘Hi-D::EGF phage’) (Nicastro et al., 2013). Phages generated from the SupF E. coli 
strain resulted in reduced complementation from the plasmid expressing the gpD fusion than the 
SupE E. coli strain, therefore phages generated from SupF was used in this experiment to 
represent minimal surface decoration (denoted as ‘Lo-D::EGF phage’). Fluorimetric analysis of 
gpD::eGFP decorated phages in the same study estimated about 147 molecules per phage for the 
maximal fusion (SupD, 37 ᵒC), and 89 molecules per phage generated from SupF at 37 ᵒC. From 
these values, we can infer that the Lo-D::EGF phages will be approximately 40% less decorated 
than Hi-D::EGF phages. These values are not absolute and have been provided as a point of 
reference to infer the relative degree of surface decoration.  
3.4.2 Phage lysate preparation 
Transformed SupD and SupF E. coli cells were grown in LB broth over night at 37 ᵒC. 10-fold 
dilutions of primary lysates were prepared in 1 ml of TN buffer and were added to 0.3 ml of the 
transformed cells (grown to OD600 = 0.4 at 37 ᵒC), then incubated overnight at 37 ᵒC. 10 ml of 
TN buffer were added the next day on to each plate and incubated for 24 h at 4 ᵒC. The top agar 
was scraped and transferred to a conical tube, which was centrifuged at 23183 x g (Avanti J-E 
Centrifuge, Beckman Coulter, Mississauga Canada) at 4 ᵒC for 20 min. Negative control λF7 
generated with a double suppressor BB4 E. coli host (that will not confer phage display, denoted 
as wildtype λ phage herein) was prepared in parallel for future experiments.  
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3.5 Phage purification  
All phage lysates were filtered through a sterile 0.2 µm syringe filter to remove cellular debris, 
followed by polyethylene glycol (PEG) -precipitation (Sigma-Aldrich). Precipitated phages were 
resuspended in DMEM supplemented with 5% FBS and were further purified through a gel 
chromatography. This is comparable to that purification via CsCl centrifugation in dissociating 
unincorporated fusion and other smaller cellular debris (Zakharova et al., 2005). Phage samples 
were resuspended in DMEM and 5% FBS and standardized to a concentration of 109 PFU/ml. 
100 µl of each sample was added to each spheroid for a total of 108 PFU.  
3.6 Phage titration and standard plaque forming unit assays 
Plaque assays were used to determine concentration of phages following the purification process. 
It was also used to assess change in phage infectivity over time under various conditions. Soft-
agar overlay technique was used on fresh BB4 E. coli cells, as this strain generates the highest 
titers of λF7 (it possesses double suppressor activity, SupE, SupF). A liquid culture of BB4 (300 
µl) was added to 3 ml of molten top agar (Bacto Tryptone and Bacto Agar from Difco 
Laboratories, Sparks, MD), as well as a 100 µl volume of phage dilution in suspension. Each 
phage particle produced a visible clearing zone on the lawn of bacteria; greater dilution of 
phages in the supernatant resulted in fewer plaques. Solutions containing purified phage were 
generally standardized to 109 PFU/ml and 100 µl (108 PFU) was added to each spheroid, unless 
otherwise stated. 
3.7 Assessing phage viability  
To test the infectivity of phages under the experimental conditions outlined, changes in phage 
titers were measured over time using the plaque assay. Wildtype and gpD::EGF expressing 
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phages were incubated at both 4 and 37 ᵒC, suspended either in DMEM supplemented by 5% 
FBS or TN buffer, and were then measured at 4, 8, 24, and 48 h, post-application. Phages were 
quantified on E. coli BB4 cells and were plated on LB agar, diluted in TN buffer by a standard 
factor to generate countable plaques within the ranges of 20-200 PFU/plate. Efficiency of plating 
(EOP) was expressed relative to the initial phage titer determined at t = 0 h as the 100% plating 
control.  
3.8 EDTA sensitivity assay 
Structural stability of phages displaying EGF molecules were tested using the EDTA sensitivity 
assay. Phages were diluted in TN buffer (0.01 M Tris-HCl and 0.1 M NaCl, pH 7.8; Fisher 
Scientific, USA) to a standardized concentration of 108 PFU/ml, then were diluted 100-fold into 
TN/EDTA buffer (0.01 M Tris-HC; (pH 7.8), 0.1 M NaCl, and 0.01 M EDTA) and incubated for 
30 min at 25 °C. The EDTA-phage reaction was stopped by diluting experimental reactions 100-
fold into TN buffer. Phages were then plated on an overlay of BB4 cells and incubated overnight 
at 37 °C. EOP was determined for each sample, using the formula below:   
plaque counts by the original phage concentration 
100% positive plating control (using plaque counts on BB4 cells)
  
3.9 Labeling of phage capsid for imaging 
 
The primary amines of wildtype λ phage or EGF-displaying phage capsids were conjugated with 
Alexa Fluor® 488 (Thermo Fisher) according to manufacturer’s instructions. Briefly, 1012 PFU 
of PEG-precipitated phages were resuspended in 95 µl of 0.1-M NaHCO3 buffer (pH 8.3) and 
were incubated with 5 µl of dye (10 mg/ml in dimethyl sulfoxide, (DMSO) at room temperature 
for 1 h with brief vortexing every 10 min. The volume was then brought up to 1 ml and was 
centrifuged for 30 min at 23183 x g at 4 ᵒC, then for 10 min at the same speed. The unbound dye 
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in the supernatant was replaced with DMEM and 5% FBS to resuspend the Alexa Fluor® 488- 
conjugated phages.  
3.10 Confocal microscopy for phage visualization in spheroids 
HT29 spheroids were grown for 7 d (seeding density of ~5,000 cells). Spheroids were transferred 
into 1.5 ml microcentrifuge tubes and treated with 108 PFU of phage for either 30 min, 4 h, 8 h 
and 24 h and incubated at 37 ᵒC, 10% CO2. Each spheroid was stained with 10 µM of 
CellTracker Red CMPTX dye™ (Molecular Probes, Invitrogen) for 1 h at 37 °C prior to 
visualization. CellTracker is mildly thiol-reactive and can diffuse through the live cell 
membranes. It is retained in the cell for at least 24 h as it becomes membrane-impermeable by 
reacting with other intracellular proteins (Gonzalez et al., 2013). Cell medium was discarded, 
and spheroids were washed 3X with PBS and transferred with a glass pipette onto a glass 
bottomed 24-well plate (MatTek P-24G-0-13_F). Treated spheroids were visualized with laser 
scanning confocal microscope, 20X objective (Zeiss LSM 710). Z-stack images from the bottom 
to the center were obtained for each spheroid. Confocal microscopy was done with the assistance 
of Drs. M. Foldvari and R. Chen and J. Fux.  
3.11 Internalization assay  
HT29 spheroids were grown for 7 d (seeding density of ~5,000 cells). Prior to the application, 
spheroids were treated with 5 mM of NH4Cl for 45 min at 23 °C to prevent internalized phages 
from entering the lysosomes. Ammonium chloride and chloroquine are considered to be 
lysosomotropic weak bases that selectively accumulate in lysosomes to reduce endosome-
lysosome acidification (Misinzo, Delputte, & Nauwynck, 2008). Spheroids were washed with 
PBS and treated with 108 PFU of phages for 30 min, 4 h, 8 h and 24 h at 37 °C. Following the 
incubation periods, spheroids were washed 5 times with PBS to remove unbound phages. Cold 
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0.2 M glycine (pH 2) was added to spheroids for 10 min, followed by 2 washes with PBS to 
inactivate unassociated phages suspended in the media. 100 μl of 0.25% EDTA-trypsin was 
added to spheroids and incubated at 37 °C for 20 min, then cells were vigorously pipetted and 
gently vortexed for complete disaggregation. The suspended cells in trypsin were centrifuged at 
7,000 x g for 10 min to separate the phages recovered from the intercellular spaces of the 
spheroids. The supernatant was removed and set aside as “intercellular” phages for each sample 
(Fig. 4). The pelleted cells were resuspended and washed in PBS, and the centrifugation step was 
repeated. The wash media was collected in the same “intercellular” fraction. The pelleted cells 
were resuspended in 100 μl MilliQ H2O, subjected to 3 freeze/thaw cycles to release internalized 
phage particles. This mixture was centrifuged and the supernatant was set aside as the 
“intracellular” fraction of the phage mixture. The collected fractions were serially-diluted by 10-2 
– 10-8 in PBS, and 10 µl of each dilution of phages were “spotted” onto a lawn of BB4 cells to 
determine the optimal dilution factor for well-separated, countable plaques. These plates were 
incubated overnight at 37 °C and whole plates were prepared the next day to determine the EOP 




Figure 4: Internalization assay. Spheroids were pre-treated with ammonium chloride prior to 
the addition of phages for 0.5, 4, 8 and 24 hours. Spheroids were washed with PBS to discard 
unbound phages on the surface of spheroids. Spheroids were then completely dissociated with 
trypsin-EDTA to release intercellular phages within the spheroid. Cells were lysed by freeze-
thawing, which released intracellular phages. All recovered phages were quantified using the 
plaque assay. 
3.12 Phage λ and effects on spheroid growth 
5,000 HT29 cells were seeded on agarose to form spheroids previously described (see 3.2). 
Phages were added to partially-formed and fully-formed HT29 cells; cells were also co-seeded 
with phages to observe the effects of phages on initial cell-aggregation (detailed below). The 
following conditions were imaged with brightfield illumination on a Leica DM2000 microscope, 
10X objective and a QImaging Micropublisher 5.0 RTV camera using the QCapture Pro™ 7 
Software (QImaging). No phages were added to the “control spheroid”. All images were 
qualitatively representative of three replicates of two independent experiments:   
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i. Cells were grown for 48 h on agarose for initial aggregation for partially-formed 
spheroids prior to the addition of 108 or 104 PFU of resuspended D::EGF or wildtype λ 
phages. Pictures were obtained every 2 d over a duration of 20 d. 
ii. Cells were co-seeded with 108 or 104 PFU of D::EGF or wildtype phages and were grown 
for 7 d. Pictures were obtained every 2 d over a duration of 7 d.  
iii. Cells were pre-chilled with 108 or 104 PFU of D::EGF or wildtype phages for 1 h on ice, 
then co-seeded on to agarose. Pictures were obtained over a duration of 10 d.  
iv. Fully-formed HT29 spheroids, cultured for 5 d (seeded at 3,000 cells), were treated with 
108 or 104 PFU of D::EGF or wildtype phages. Pictures were obtained over a duration of 
5 d.   
3.13 MTT assay 
The size of the viable cell population with the treatment of phages was measured by the 3-(4,5-
dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay and its conversion to 
formazan by viable cells. Cells were seeded in DMEM supplemented with 5% FBS in 96-well 
plates and incubated at 37 °C, 10% CO2 for 48 h to allow for initial adherence. Cells were then 
treated with either 108 or 104 PFU of D::EGF or wildtype phages for 24 h at 37 °C, 10 % CO2. 
The medium was aspirated and 20 μl of 0.5 mg/ml MTT in PBS was applied and the plate was 
swirled and incubated at 37 °C for 1 h to allow for the conversion of MTT into formazan. The 
MTT reagent was then removed and replaced with 100 μl of DMSO per well for 30 min at room 
temperature for the dissolution of formazan dye. At the end of this incubation period, the 
absorbance of the plate was measured at A492 nm on a SpectraMax M5 Plate Reader. The results 
were normalized by subtracting A492 of blank wells. 
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3.14 3D Toxicity assay  
Phage-treated HT29 spheroids were assessed for cytotoxicity using CellTiter-Glo® 3D 
(Promega) – a viability assay for 3D cell cultures. It determines the number of viable cells in 
multicellular spheroids based on the quantitation of ATP, a marker for metabolically-active cells. 
This assay was used to visually determine whether cells within spheroids remained viable in 
response to phage treatment. This was conducted according to the manufacturer’s directions, as 
follows. 5,000 HT29 cells were seeded to produce robust spheroids, as previously described, and 
grown for 7 d. Spheroids were transferred with glass pipettes and placed into opaque multiwell 
plates. A volume of acid solution (4 mM diaminocyclohexane triacetic acid in water) was added, 
equivalent in volume to the cell culture medium containing the spheroid. The contents were 
mixed vigorously for 5 min on an orbital shaker and incubated at room temperature for 
additional 15 min. Half of the sample was transferred to a separate container and diluted by 10-
fold in MilliQ H2O with repeated mixing to ensure homogeneity. The diluted sample was then 
transferred to a fresh assay well. An equal volume of CellTiter-Glo® 3D Reagent was added, and 
the contents were mixed for an additional 2 min on an orbital shaker. The plates were incubated 
at room temperature for 10 min to stabilize the luminescent signal, which was then recorded on 
the SpectraMax M5 spectrophotometer using the luminescence mode at the wavelength range of 
250–850 nm.    
3.15 Spheroid embedding in paraffin 
HT29 spheroids grown for 7 d (seeding density of 5,000 cells) were treated with fluorescently-
tagged wildtype or D::EGF phages (see 3.8). The spheroids were placed in 20X volume of 10% 
formalin at room temperature and dehydrated by passing through successive changes of 70% 
ethanol (in Millipore water), two changes in 100% ethanol and two changes in 100% xylene. The 
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spheroids were embedded into paraffin wax by passing through two changes of 100% wax at 56 
– 58 ᵒC. The sections were mounted onto slides and air dried. The sections were deparaffinized 
the following day in 2-3 changes of xylene, 5 min each. Sections were then hydrated in 2 
changes of 100% ethanol for 3 min each, 70% ethanol for 1 min each. Samples were fully 
hydrated with 2 changes of MilliQ H2O and mounted with aqueous mountant (Biomeda©).   
3.16 Statistical analysis 
GraphPad Prism 5 software was used for the analysis of data and a threshold of p<0.05 was 
deemed to be significant for all statistical tests. Changes in phage viability in response to 
temperature was analyzed by two-way analysis of variation (ANOVA) by comparing values 
between incubations at 4 ᵒC and 37 ᵒC. HT29 spheroids treated with ammonium chloride was 
compared with the untreated by the Mann-Whitney test. Percent internalization of D::EGF 
phages were compared to that of wildtype for each treatment durations by the Mann-Whitney 
test. Percent viability of HT29 cells in response to phage treatment was compared to the 
untreated cells by the Mann-Whitney test. Experiments were performed with a minimum of three 











Chapter 4: Results 
4.1 Characterization of spheroids with different seeding densities 
Cells were seeded on agarose, which resists cell adhesion and causes the cells to preferentially 
stick to each other and form spheroids. The growth of spheroids and morphological changes 
were monitored for the following cell lines: HT29, MDA-MB-231, A549 and A2780. Growth of 
spheroids were visualized with a bright-field microscope for up to 10 d to choose optimal cell 
lines for downstream applications.  
 
Figure 5: Growth of HT29 spheroids at various seeding concentrations, imaged for 10 d. 
Spheroids seeded with more than 10,000 cells were generally flatter in morphology. These cells 
dispersed laterally onto agarose, which could not be used to assess phage penetration. 6-10 day-




Figure 6: Growth of A549 spheroids at various seeding concentrations, imaged for 10 d. 
Spheroids demonstrated poor reproducibility and were also generally flatter in morphology.  
 
 
Figure 7 Growth of MDA-MB-231 spheroids at various seeding concentrations, imaged for 





Figure 8: Growth of A2780 spheroids at various seeding concentrations, imaged for 10 d. 
Cell-cell connections appeared to be loose and gaps were visible between cells. Spheroids did 
not form fully and appeared to be disc-like in morphology. 
Fig. 5-8 shows representative optical images of spheroids with different cell seeding densities. 
Several stages were uniformly observed in spheroid formation across most cell lines; within the 
initial 24 h after seeding, cells spontaneously aggregated and appeared to form of intercellular 
connections.  However, MDA-MB-231, A549 and A2780 spheroids were not robust and 
disintegrated upon handling. A2780 spheroids in particular, showed dispersed cells with visible 
intercellular gaps after 10 d, likely having failed in forming effective cell-cell connections (Fig. 
8). Conversely, robustness was achieved within 6-10 d of growth for HT29 cells seeded at a 
concentration of 5,000 to 30,000 cells (Fig. 5). Definite intercellular connections appeared to 
have established by days 3-5, as the surfaces of spheroids were smoother and diameters 
decreased slightly. This was likely a result of cells adhering more tightly to each other. 
Diameters increased again by day 6, and cell proliferation was visible on days 4-6. Spheroids 
exhibited rougher edges and cells scattered in the surrounding media. Cells visibly dissociated 
from spheroids on day 10, as cells lost their circular morphology. The relationship between cell 
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seeding concentrations and spheroid diameters for cell lines HT29, NIH3T3 and HCT116 after 5 
d of growth are shown in Table 2.  
1Diameters are represented as a mean ± SEM of 3 separate spheroids.  
2
N/A denotes the insufficient cell density for effective aggregation and ability to form a defined spheroid.  
Diameters of each group were highly uniform (SD <15%).  
HT29 cells were selected for downstream applications because diameters were uniform and 
reproducible – 90% of wells formed spheroids and diameters varied by less than 15% (Table 2). 
Reproducibility of spheroid sizes was crucial to ensure consistency in parameters that could 
ultimately influence the pharmacokinetics of phage penetration. However, it is important to note 
that individual spheroids can still be highly heterogeneous despite exhibiting similar diameters. 
HT29 cells can also be useful in modeling epithelial cells forming tight junctions between cells 
(Martínez-Maqueda, Miralles, & Recio, 2015). In this project, ~350 μm diameter HT29 
spheroids, initially seeded with 5,000 cells and grown for 6-10 d were often used for treatment. 
Larger spheroids may exhibit hypoxic and necrotic cores, which may potentially complicate the 
characterization of phage penetration because of accumulated fluid and cellular debris (Zanoni et 
al., 2016).  
Table 2: HT29, NIH3T3 and HCT116 spheroid diameters are dependent on initial cell-
seeding densities.   
Seeding Densities Diameter of NIH3T3 
spheroids (µm)1 
Diameter of HT29 
spheroids (µm) 1 
Diameter of HCT116 
spheroids (µm) 1 
100 N/A2 70 ± 8.2 N/A 
500 N/A 175 ± 19.2 150 ± 18.2 
1,000 N/A 205 ± 20.4 175 ± 19.7 
5,000 70 ± 10.5 320 ± 35.1 225 ± 28.3 
10 000 130 ± 15.9 580 ± 50.3 530 ± 41.2 
20 000 190 ± 16.2 700 ± 66.4 615 ± 50.8 
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The complete aggregation of cells to form robust spheroids was also contingent on the initial 
seeding densities. For example, the initial concentration of < 1,000 cells was not sufficient for 
aggregation after 7 d and failed to form defined spheroids (Fig. 9). HT29 spheroids seeded with 
≥10,000 cells were compact and usable for downstream applications 
 
Figure 9: HT29 cells seeded at various concentrations after 7 d. Cell proliferation was 
evident by the scattered cells surrounding the spheroids. Seeding fewer than 1,000 cells resulted 
in aggregation of cells, but they failed to form defined spheroids. 
4.2 Generation of EGF-displaying λ phages and λ packaging tolerance of 
gpD::EGF fusion 
The ability of the pD::EGF plasmids to complement the Dam15 mutation of λF7 to generate 
phages displaying EGF was dependent on the tolerance of the gpD allele conferred from the 
SupD and SupF isogenic suppressor strains. Theoretically, poor suppression of the amber 
mutation by the Sup+ hosts would lead to the greater reliance on the pD::EGF plasmids for 
complementation of gpD. This was determined by assessing the restoration of viability of λ 
Dam15 phages generated from the different Sup+ hosts as compared to the Sup− wild type E. 
















































Table 3: pD::EGF complements the Dam15 mutation and increases 






Increase in plating (compared to 
Sup-) 
Sup− 2.8 x 10-5 1.0 
Sup−  [pD::EGF] 0.05 1.79 x 103 
SupD 1.6 x 10-5 0.57 
SupD [pD::EGF] 0.12 4.29 x 103 
SupF  0.23 8.21 x 103 
SupF [pD::EGF] 0.10 3.57 x 10
3 
1
The E. coli suppressors are W3101 derivatives, and the plasmid pPL451 is under the temperature-regulated 
repressor CI857.  
2
All EOPs have been expressed as a mean of three assays with 3 replicates, determined using BB4 (SupE, SupF 
double suppressor E. coli) as the 100% plating control, plated at 37ᵒC.  
 
Table 3 shows the ability of the gpD::EGF expression plasmid to complement for the Dam15 
mutation of λF7 by restoring plating by more than a 1000-fold in the absence of suppressor 
activity (Sup−). The EOP (determined by BB4, SupE, SupF double suppressor, as the 100% 
plating control) increased by over a 4000-fold in SupD with the gpD::EGF complementation 
despite the poor suppressor activity and low viability on the SupD derivative. SupF strain 
possesses effective suppressor activity and there were no significant differences with the 
complementation for the Dam15 mutation on the viability of phage. These results were in 
agreement with those of Nicastro et al. 2013, whereby the SupD host was the least effective at 
reversing the Dam15 mutation, while SupF suppressed the mutation with near perfect efficiency 
(Nicastro et al., 2013). Plasmid pPL451 is under the control of a temperature-sensitive repressor, 
CI857, but all phages were generated at 37 ᵒC, rendering the repressor ineffective and allowing 
the expression of downstream gene sequences. This resulted in maximal fusion of EGF to gpD 
on the λDam15 phage capsid at 37 ᵒC, specifically in the suppressor host with the poorest 




4.2.1 Assessment of phage viability in response to temperature 
Phages are typically stored at 4 ᵒC, which generally provides long-term stability (Lech, Reddy, & 
Sherman, 2004). The effects of long-term incubation at 37 °C and in cell media on the ability of 
wildtype and EGF-displaying phages were assessed. Phages were exposed to these conditions for 
defined intervals up to 48 h and plaque assays were used to quantify changes in the concentration 
of infective phage particles over time.   
Table 4: Prolonged exposure of phages at 37ᵒC decreases λ phage infectivity. 
  
EOP of λF7 
incubated at 4ᵒC1  
EOP of λF7 
incubated at 
37ᵒC1 
EOP of D::EGF 
phages  
incubated at 4ᵒC1 




0 h 1.00 ± 0.02 1.00 ± 0.05 1.00 ± 0.05 1.00 ± 0.02 
4 h  0.98 ± 0.01 0.91 ± 0.01* 0.95 ± 0.04 0.57 ± 0.02**** 
8 h  0.86 ± 0.05 0.73 ± 0.02*** 0.82 ± 0.05 0.43 ± 0.04**** 
24 h  1.12 ± 0.02 0.46 ± 0.02**** 0.86 ± 0.03 0.19 ± 0.08**** 
48 h 0.94 ± 0.03 0.35 ± 0.03**** 0.86 ± 0.02 0.28 ± 0.04**** 
1All EOPs have been expressed as a mean ± standard deviation of three independent assays, n=3, determined using 
BB4 (SupE, SupF double suppressor) as the 100% plating control and plated at 37 ᵒC.  
Comparisons of each phage types at two temperatures were made for each treatment period using the 2-way 
ANOVA test. Viability decreases of both phage types at 37 ᵒC were statistically significant for all treatment periods.   
 
This viability assay provides a relative change in phage titers; it is not an accurate representation 
of total phage particle counts in the media. Re-suspension and dilution of phage incubations in 
cell media supplemented at 4 ᵒC slightly reduced phage infectivity, but this effect on phage 
viability increased dramatically at 37 ᵒC. Changes in phage viability for both phage types with 
higher temperatures were statistically significant at all treatment durations, but D::EGF phages 
were impacted more by these external conditions than the wildtype λF7 phages. To minimize the 
effects of external variables on experimental outcomes, all titer assays were expressed as EOPs 
to the PFU/ml of the phage concentrations at each set of conditions in Table 4 to accommodate 
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for these confounding variables. All experiments were conducted with maximum incubation 
periods extending up to 24 h at 37 ᵒC, as phage titers were decreased dramatically by this time 
point.  
4.2.3 EDTA resistance by λ wildtype and λ D::EGF phages 
Phages expressing EGF decoration were assessed for structural integrity with incubation in 
EDTA. EDTA is a chelating agent and will sequester cations such as Mg2+ and Ca2+, which are 
necessary co-factors to destabilize the λ capsid (Gilcrease et al., 2005).  
Table 5: Susceptibility of Display 





SupD [pD] 0.41 ± 0.03 
SupD [pD::EGF] 0.62 ± 0.02 
SupF [pD] 0.46 ± 0.06 
SupF [pD::EGF] 0.61 ± 0.04 
Sup− [pD::EGF] 0.21 ± 0.05 
Sup−[pD] 0.89 ± 0.03 
1All EOPs have been expressed as a mean of three assays determined using BB4 (SupE, SupF double suppressor) as 
the 100% plating control and plated at 37 ᵒC.  
Phages grown on SupD E. coli had a lower survival rate (41%) than lysates grown on SupF 
(46%), which may be attributed to the higher stability in packaging. Decoration of the gpD 
protein resulted in consistent survival rates of 62% and 61% for the maximal decoration and 
minimal decoration, respectively. Phages developed on Sup− [pD::EGF] exhibited low survival 
rates of 21%, which may indicate low tolerance for the incorporation of the D::EGF into the 
phage capsid. Combination of complementation with pD::EGF and gpD alleles was found to be 
more stable than either one alone. Sup−[pD] conferring the wildtype gpD allele had the greatest 
resistance to EDTA at 89%, as expected.  
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4.3 Bacteriophage λ infiltration of multicellular spheroids 
To demonstrate λ association and infiltration into the spheroids, 3 μm cross-sectional Z-stack 
images of spheroids were obtained with an inverted confocal microscope. The inner, densely-
packed regions of the spheroid could not be observed, where the scattering of light obscured the 
detection of fluorescent phages in these regions. General observations were made on the spheroid 
surface-phage interactions as well as the overall accumulation of phages in the visible regions of 
the spheroid.   
4.3.1 Interaction of λ phages with NIH3T3 spheroids 
First, in order to observe the native interaction between unmodified, wildtype phages and 
fibroblast spheroids, 108 PFU of wildtype λF7 phages tagged with Alexa Fluor® 488 were added 
to each 6- d old NIH3T3 spheroid for 0.5, 6 and 24 h. Spheroids were washed to discard 
unbound phages and were stained with CellTracker (red) (Fig. 10). After 6 h of treatment, the 
phage-associated fluorescence (green) was concentrated primarily at the periphery of the 
spheroid and were visible in the spheroid depths of 25 µm. After 24-h of phage treatment, phage-
associated fluorescence completely dominated all cross-sections of the spheroid, likely indicating 





Figure 10: Optical cross-sections of NIH3T3 spheroids treated with fluorescent λ phages. 
Representative images of spheroids treated for A. 30 min, B. 6 h, and C. 24 h at optical sections 
25, 55 and 90 µm from the bottom-most surface (n=3). All the spheroids were counterstained 
with CellTracker™ Red prior to imaging. Green fluorescence is associated with the presence of 
Alexa Fluor 488- phages. 
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The purification process of phages involved precipitation of phages by polyethylene glycol 
(PEG). This raised the possibility of PEG being bound by Alexa Fluor 488 and providing false 
positive signals in Fig. 10. Therefore, PEG was processed with Alexa Fluor 488 as a control, 
without the addition of phages, in Fig. 11.    
 
Figure 11: NIH3T3 spheroid treated with polyethylene glycol. Representative images of 
NIH3T3 spheroids treated with A: unlabeled λ phages, B: polyethylene glycol (PEG) without the 
addition of phages subjected to Alexa Fluor 488 reaction; and C: Alexa Fluor 488- λ phages. 
Spheroids were treated for 0.5, 6 and 24 h. Optical sections 55 μm from the bottom of spheroids 
are shown. All the spheroids were counterstained with CellTracker™ Red prior to imaging. 
Green fluorescence is associated with the presence of Alexa Fluor 488- phages. All images are 
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The very low signal in the PEG-only control in Fig. 11 suggests the view that the strong green 
fluorescence observed in Fig. 10 was very likely emitted by tagged phages. We can infer that 
phages began to adhere to the surface of the spheroid as early as 0.5 h and diffused through the 
intercellular spaces, freeing up the external surface of cells at 6 h. More phages bound to the 
external surface of spheroids and accumulated in a time-dependent manner up to 24 h (Fig. 10). 
Based on these results, there appears to be a great level of natural interaction between 
unmodified, wildtype λ phages and NIH3T3 fibroblasts, and infiltration into NIH3T3 spheroids 
likely occurs as early as 6 h after 108 PFU of phage application. 
4.3.2 Interaction of λ D::EGF phages with HT29 spheroids 
Spheroids were generated from HT29 cells to study phage accumulation in the context of rapidly 
proliferating neoplastic cells that form tight cell-cell contacts (Riffle & Hegde, 2017).  
Additionally, we wished to observe potential changes in phage-spheroid interactions with the 
display of EGF on the same phage (λ). EGFR is overexpressed in HT29 cells and has been 
associated with aggressive biological behaviour (Grandis et al., 1998; Yang et al., 2004). D::EGF 
phages (EGF fused to gpD capsid proteins) were generated for maximal fusion of molecules 
(grow on the SupD host at 37 ᵒC). 108 PFU of either the wildtype and D::EGF phages were 
added to HT29 spheroids (~300 µm diameter) for up to 24 h, and Z-stack images were obtained 
at 12 and 24 μm depth from the bottom surfaces (Fig. 12, 13).  




Figure 12: Optical cross-sections of HT29 spheroids treated with wildtype phages and EGF-
displaying phages for 30 min (top) and 4 h (bottom). 6-d old HT29 spheroids (~300 μm 
diameter, seeded with 5,000 cells) treated with Alexa Fluor 488 tagged phages (green) for given 
durations. Z-stacks were obtained at 12 and 24 μm from the bottom-most surface of the spheroids. 
All images are qualitatively representative of three replicates of spheroids. 
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Figure 13: Representative cross-sections of HT29 spheroids treated with wildtype phages and 
EGF-displaying phages for 8 h (top) and 24 h (bottom). Continued from Fig. 9 
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Fluorescent wildtype (EGF—)  phages were visible on the outer edges of the surface of HT29 
spheroid as early as 4 h. Spheroids treated with D::EGF phages were relatively free of 
fluorescence until after 8 h of treatment. After 24 h, positive fluorescence was visible in the 
spheroids treated with both types of phages at 12 and 24 μm depths. Positive fluorescent spots 






Figure 14: Collective Z-stacks of HT29 spheroids treated with A. EGF-displaying phages 
and B. wildtype phages (bottom) for 24 h. Each square represents 3 μm slices of spheroids 
from the bottom-most surface (top left) to the centre (bottom right). 6-day old HT29 spheroids 
(~300 μm diameter, seeding concentration of 5,000 cells) were washed to discard unassociated 
phages (green) after incubation periods. 
Fig. 14 shows the collective Z-stacks of HT29 spheroids treated with D::EGF phages (Fig. 14A) 
and wildtype phages (Fig. 14B) after 24 h. There were noticeably more green fluorescent spots 
embedded in the spheroid treated with λ D::EGF phages than with wildtype phages, in all optical 
sections. There also appeared to be more fluorescent particles floating in the medium of the 






This may have been a result of more loosely-bound phage particles on the spheroid coming 
unbound and settling to the surface, after spheroids were transferred.  
4.4 Bacteriophage λ internalization by HT29 cells 
Certain spots of positive green fluorescence exhibited diffuse edges, appearing to be confined by 
the boundaries of the cell membranes (yellow arrows, Fig. 15). This suggested the possibility 
that they were emitted from within cells, rather than from the surface of the cells. Intracellular 
fluorescence suggest that the phage-associated particles have been internalized by HT29 cells. 
We queried other studies involving the use of confocal imaging to visualize cells stained with 
CellTracker to use as a point of reference for the appearance of these internalized, fluorescent 
particles. A study by Bhagawat et al. (2018) showed α3 integrin antibodies labeled with Alexa 
Figure 15: Phage-associated fluorescence emitted inter- and intracellularly of HT29 cells. Diffused 
pattern of green fluorescence signal suggests a possible internalization of phages by the HT29 cells (yellow 
arrows); discrete fluorescent dots suggest the surface localization of phages (white arrow).  HT29 spheroids 
were treated with wildtype phages (left) and EGF-displaying phages (right) for 4 h 
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Fluor 488 internalized by cells stained with CellTracker Red (Subramanian, Moissoglu, & 
Parent, 2018). Once internalized, these antibodies also appeared yellow with diffuse edges.  We 
determined that the extracellular fluorescence would appear more discrete with distinct edges, 
such as those indicated by white arrows in Fig. 15.   
4.4.1 Quantitation of internalized bacteriophage λ particles 
To further investigate the potential cellular uptake of phages by HT29 cells, cells comprising the 
spheroids were lysed to release internal contents and the PFU was quantified by a conventional 
plaque assay. Previous studies have shown that recovered intracellular phages can retain their 
infectivity after 24 h (Kim et al., 2012). However, as phages are not stable at 37 oC outside of a 
bacterial host, this temperature was expected to reduce overall viability counts (Table 4). 
Additionally, to investigate the potential D::EGF-EGFR association, λ D::EGF phage decorated 
with fewer molecules,  approximately 40% fewer per phage (Lo-D::EGF phage) than the 
achievable maximal decoration (Hi-D::EGF phage), was generated using the SupF E. coli host 
(see 4.3.1) (Nicastro et al., 2013) . The purpose of generating a less-decorated phages was to 
determine whether the phage-cell association would be reduced in response to the decreased 
avidity of the presumed D::EGF-EGFR interaction. These phages were also fluorescently tagged 
and added to HT29 spheroids similarly as above, alongside the Hi-D::EGF phages and wildtype 
phages.  
In order to minimize intracellular trafficking of phage particles into lysosomes, spheroids were 
pre-treated with a lysosomotropic agent (ammonium chloride) prior to the addition of phages. 
This was expected to minimize the degradation of phage particles that would underestimate the 
overall quantitation of internalized phage particles, First, the effects of ammonium chloride in 
improving phage viability was assessed by comparing the enumeration of wildtype phage 
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recovered from pre-treated spheroids to untreated spheroids (Fig. 16). Cells were lysed using the 
freeze-thaw method, and in order to fully recover internalized phages by cells situated closer to 
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Figure 16: Testing the action of ammonium chloride as a lysosomotropic agent to improve 
phage recovery. 6-d old HT29 cells (seeding density of 5,000 cells) were treated with 5mM of 
ammonium chloride for 45 min at room temperature. Following treatment, remaining ammonium 
chloride was removed and 108 PFU of wildtype phages were added to spheroids for up to 24 h. 
Spheroids were completely dissociated with 0.25% trypsin-EDTA and washed to discard 
extracellular phages. Cells were subjected to freeze-thaw cycles for lysis and release of phage 
particles. Phages recovered from lysed cells were plated on BB4 E. coli cells for quantification 
of plaques. Data is presented as the mean + SEM of three independent experiments, carried out 
in triplicates. Differences in PFU between treated and untreated were not determined to be 








Furthermore, to ensure that exposure to trypsin-EDTA was not going to deactivate phages, 
viability assays were also conducted on phage particles resuspended in different concentrations 
of trypsin-EDTA at 37 ᵒC for 1 h (Table 6).   




EOP of λF7 
incubated at 
37ᵒC1 
EOP of D::EGF 
phages  incubated at 
37ᵒC1 
0 % 1.00 ± 0.01 1.00 ± 0.02 
0.10 % 0.89 ± 0.03 0.87 ± 0.03 
0.25 % 0.89 ± 0.07 0.89 ± 0.09 
0.50 % 0.84 ± 0.07* 0.79 ± 0.07** 
1.00 % 0.72 ± 0.10** 0.76 ± 0.12* 
1All EOPs have been expressed as a mean of three independent assays and determined using BB4 (SupE, 
SupF double suppressor) as the 100% plating control and plated at 37 ᵒC.  
Reductions in viability of D::EGF and wildtype phages were not statistically significant using the 2-way 
ANOVA for 0 – 0.25% trypsin EDTA.  
 
The pre-treatment of spheroids with ammonium chloride on the yield of internalized phages was 
not determined to be significant. However, treatment enhanced the recovery of phages for up to 8 
h, but appeared to be slightly detrimental in recovering phages after 24 h (Fig. 16). Pre-treatment 
of spheroids with ammonium chloride was carried out for the internalization assays (Table 7).  
Phages were recovered from intercellular spaces of spheroids and intracellularly from lysed cells. 
Differences in phage recovery were compared between the wildtype and Hi-D::EGF phages after 
0.5, 4, 8 and 24 h of treatment, to determine whether D::EGF-EGFR interactions would increase 
the percentage of internalized cells (Fig. 17). To minimize possibly scoring extracellular phages 
that were bound to the surface of cells as intracellular, we incubated the cells with an acidic wash 
(pH 2) to inactivate the phages. However, this technique does not inactive 100% of phages, as 
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such a background of extracellular bound phages is inevitable (Lehti et al., 2017). Counts in 
Table 7 should be considered as relative.  
EOP’s in Table 6 were corrected by taking account of the viability decrease at 37 ᵒC (Table 3) as 
the 100% control using the formula:  
𝑎𝑑𝑗𝑢𝑠𝑡𝑒𝑑 𝐸𝑂𝑃 =  
𝑃𝐹𝑈 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟− 𝑜𝑟 𝑖𝑛𝑡𝑟𝑎𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝑝ℎ𝑎𝑔𝑒𝑠
108𝑃𝐹𝑈 × 𝑝𝑒𝑟𝑐𝑒𝑛𝑡 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 
  
 
PFU of recovered inter and intracellular phages were expressed as ‘percent internalization’ in 
Fig. 17 by using formula: 
 
𝑎𝑑𝑗.  𝐸𝑂𝑃 𝑜𝑓 𝑖𝑛𝑡𝑟𝑎𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝑝ℎ𝑎𝑔𝑒𝑠
𝑎𝑑𝑗.  𝐸𝑂𝑃 𝑜𝑓 𝑖𝑛𝑡𝑟𝑎𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝑝ℎ𝑎𝑔𝑒𝑠 + 𝑎𝑑𝑗.  𝐸𝑂𝑃 𝑜𝑓 𝑖𝑛𝑡𝑒𝑟𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟 𝑝ℎ𝑎𝑔𝑒𝑠
 × 100% 
 
  














30 min Intercellular2 6.59E-04 1.27E-03 0.541 1.56E-03 0.296  
Intracellular3 5.17E-05 1.20E-04 0.779 1.30E-04 0.722 
4 h Intercellular 1.66E-02  4.10E-02  0.966 5.72E-02  0.438  
Intracellular 7.62E-05 7.35E-05  1.000 3.92E-03  0.483 
8 h Intercellular 1.03E-03 1.71E-02  0.102 1.83E-02  0.081  
Intracellular 6.36E-05 1.24E-03  0.273 1.47E-03  0.177 
24 h Intercellular 1.01E-03 7.15E-03  0.794 1.13E-02  0.475  
Intracellular 7.77E-06  4.16E-04  0.477 3.12E-04  0.653 
1All EOPs were adjusted to take account of decrease in cell viability with prolonged incubation at 37 ᵒC and are 
expressed as a mean of three independent assays + SEM, n=3, and determined using BB4 (SupE, SupF double 
suppressor) as the 100% plating control. 
2
Phages recovered from the interstitial spaces of HT29 spheroids 
3 Phages recovered from lysed HT29 cells.  
4Statistically significant differences in expression were determined by two-way ANOVA Tukey’s multiple 
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Figure 17: Percent internalization of phages determined from HT29 spheroids. The 
percentage of internalized phages that were associated with the spheroid was calculated from the 
data shown in Table 6 using the formula above. The display of EGF correlated with the mean 
percentage of intracellular phages particle intracellularly at all treatment periods. Percent 
internalization did not appear to be dependent on the density of EGF molecules displayed on the 
surface of phage. 2-way ANOVA multiple comparisons test indicated no statistically significant 
differences in the % internalization difference between WT phages and both D::EGF-phages 
p>0.05. 
The mean of recovered phages indicates that the uptake of phages by HT29 cells was enhanced 
by the display of EGF molecules; however, this was not determined to be statistically significant 
(Fig. 17). Large variances in the recovery of phages were expected as large titer of phages were 
initially added, and spheroids were manually washed to discard unassociated phages. Therefore, 
relative trends in the association must be considered instead. Substantial differences in phage 
uptake between the D::EGF phages and wildtype phages was observed at 30 min. Recovery of 
both types of EGF-displaying phage particles from the interstitial spaces and within cells were 
greater by over 150-fold than wildtype phages (Table 7). This suggests that EGF may assist in 
the initial attachment of phages to the cells, resulting to a greater percentage of internalization. 
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At 4 h, the number of phage particles associated with the spheroids extracellularly were similar 
for both Lo- and Hi-D::EGF phages (Table 7). However, the percentage of internalization was 
much higher for the Hi-D::EGF phages, suggesting a ligand density-dependent mechanism. After 
8 h, average uptake of phage particles was at peak for both D::EGF and wildtype phages, 
although there were fewer phages associated with the spheroids than at 4 h. After 24 h of 
treatment, internalized phage particles were likely degraded in the cells even with the assistance 
of ammonium chloride (Fig. 16), and it is unclear whether the quantitation provided accurate 
representation of internalized phage particles.  
 
4.5 Effects of EGF display on bacteriophage λ on spheroid growth 
To determine whether phages would interfere with spheroid growth, 5,000 HT29 cells were 
seeded on agarose and low (104 PFU) or high (108 PFU) concentrations of Lo-D::EGF, Hi-
D::EGF and wildtype phages were added after 48 h to the partially-formed spheroids. EGF 
displayed on phages were expected to bind to the EGFR on the surface of HT29, blocking cells 














Figure 18: Effects of D::EGF phages and wildtype phages on the growth of HT29 spheroids. HT29 
cells were seeded for 48 h to form partially-formed spheroids. 104 or 108 PFU of phages were added to 
each spheroid. The formation and growth of spheroids were monitored for 20 d with a bright-field 
microscope. Each picture is representative of 3 replicates of spheroids for each condition. 
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Table 8: HT29 spheroids treated with D::EGF 
phages are smaller on day 20 
Spheroid treated with:  Diameter (μm) 
Control (no phage added)2 1533 ± 47 
108 PFU Hi-D::EGF phages3 422 ± 28 
104 PFU Hi-D::EGF phages4 1329 ± 54 
108 PFU Lo-D::EGF phages5 1198 ± 19 
104 PFU Lo-D::EGF phages6 1509 ± 52 
108 PFU Wildtype phages7 1410 ± 35 
104 PFU Wildtype phages8 1473 ± 202 
1n=3 ± SD and diameters were measured with the QCapture Pro software 
2max = 1598, min = 1516  
3max = 459, min = 389  
4max = 1406, min = 1280 
5max =1218, min = 1172 
6max =1580, min = 1455 
7max =1459, min = 1377 
8max =1754, min = 1283 
 
Figure 18 shows the growth of partially-formed spheroids affected by the presence of phages. 
There were no visible differences in the morphology of spheroids until about 2 d after the 
application of phages (4 d after seeding). Adding high concentration of Hi-D::EGF phages 
appeared to have interfered in the complete aggregation of cells, which was more apparent after 
6 d of phage application (‘day 8’). By day 20, these spheroids treated with Hi-D::EGF phages 
appeared to be more dense and compact than they had been previously; they were approximately 
three-fold smaller in size than the control spheroids (Table 8). Adding a low concentration of Hi-
D::EGF phages, however, did not result in the same pattern of growth inhibition in spheroids; 
these spheroids developed similarly in shape and size to those treated with wildtype phages. 
Spheroids treated with wildtype and Lo-D::EGF phages of both high and low concentrations 
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exhibited similar sizes and density. These spheroids were slightly smaller than the control 
spheroids.   
4.5.1 Effects of EGF-displaying phages on initial cell aggregation  
Next, in order to determine whether Hi-D::EGF phages would interact with cell-surface receptors 
to disrupt initial cell aggregation, phages were co-seeded with 3,000 HT29 cells and were 
imaged with a bright-field microscope every 2 d. 
 
Figure 19: HT29 cells co-seeded with D::EGF phages or wildtype phages. Effects of phage 
presence on initial cell aggregation to form spheroids were monitored. Representative spheroids 
are shown above of three replicates of spheroids. All images were taken on a Leica DM2000 
microscope and QImaging Micropublisher 5.0 RTV camera using the QCapture Pro 7 Software. 
As shown in Fig.19, HT29 cells co-seeded with D::EGF phages and high concentration of λ 
wildtype were smaller and more compact than the control spheroids. Low concentration of 
wildtype phages did not appear to have imparted any visible effects in initial spheroid formation 
and was similar in morphology and size to the control spheroid on day 2. By day 4, cells treated 
with phages had formed smaller, compact, three-dimensional spheroids. The control spheroid 
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without phages was greater in size, but cells appeared to be sparser and loosely-associated at the 
centre. 
Phages may have settled to the agarose surface in Fig. 19, which would diminish the amount of 
phages interacting with HT29 cells. Therefore, phages were incubated with HT29 cells on ice for 
3 h to allow initial cell-phage connections to form. Pre-chilling on ice for at least 1 h is a 
common approach for blocking cellular receptors with antibodies (Vainshtein et al., 2015) and 
ligands (Schwartz, Fridovich, & Lodish, 1982). Following this adsorption phase, the cell-phage 
mixture was seeded normally onto the agarose surface (Fig.20). 
 
Figure 20: Growth of pre-chilled HT29 cells with phages. 3,000 HT29 cells were incubated 
for 3 h on ice with104 or 108 PFU of wildtype or D::EGF phages. Phages and cells were then co-
seeded onto an agarose surface and grown for 10 d. Images are representative of 3 replicates of 
spheroids. All images were taken on a Leica DM2000 microscope and QImaging Micropublisher 





Unexpectedly, lower concentrations of both wildtype and D::EGF phages appeared to assist in 
the compact packing of the cells by day 2 compared to the control. Cells co-seeded with higher 
concentrations did not fully aggregate after the first 24 h, but fully assembled by day 4. At this 
stage, spheroids treated with phages did not adopt well-defined shapes. The high concentration 
of phages adhered to the surface of cells may have obstructed the cells from fully forming cell-
cell connections. Additionally, this may have prevented cell-signaling molecules from binding to 
their surface-receptors, inhibiting growth and proliferation. There were no discernible differences 
between cells treated with wildtype phages and D::EGF phages during the initial process of cell 
aggregation in Fig. 20. Cell proliferation appeared to be much more accelerated in the control 





4.5.2 Effects of phages on fully-formed HT29 spheroids  
In order to determine whether phages can infiltrate HT29 spheroids and induce visible changes in 
spheroid morphology, 5-d old HT29 spheroids were treated with high and low concentrations of 
wildtype and D::EGF phages. 
Cell proliferation continued to occur despite the presence of phages (Fig. 21). 2 d after adding 
phages to the spheroids, there were no visible differences to the control spheroid. 5 d after adding 
both types of phages, the lag in cell proliferation was noticeable when compared to the control. 
The spheroid treated with a high concentration of Hi-D::EGF phages exhibited sparse areas 
between cells. These cells appeared to have dissociated from neighbouring cells, contributing to 
Figure 21: Effects of wildtype or Hi-D::EGF phages on HT29 spheroids grown for 5 d. Images are 
representative of 3 replicates of spheroids. All images were taken on a Leica DM2000 microscope and QImaging 






a larger diameter overall. D::EGF phages may have bound to EGFR on the surface of the cells, 
reducing the overall cell-cell contacts holding the spheroid together.  
4.6 Cytotoxicity of D::EGF λ phages to HT29 cells 
We sought to test the level of EGF-phages and wildtype phages on cell viability and performed 
an MTT assay. Cells were exposed to low (104) or high (108) PFU of phages for 24 h and HT29 
cells cultured in serum-containing medium were used as the 100% viable control (Fig. 22). The 
percentages of viability for all conditions were expressed relative to the 100% viable control. At 
the end of the 24 h exposure to phages, cell viabilities were only marginally reduced; there was 
approximately 15% reduction in HT29 cell viability in response to Hi-D::EGF phages, of both 
concentrations. The differences in viability in response to both D::EGF phages and wildtype 






















Figure 22: HT29 cell proliferation (MTT) assay in response to phage treatment 
relative to control. Cells were seeded into the wells of a 96-well plate in 9 replicates 
for each treatment group. Cells were cultured normally for 72 h before the addition of 
phages. Cells were then exposed to phages for 24 h. At the end of this period, an MTT 
assay was performed to assess cellular viability. Cells cultured normally with serum 
were considered 100% viable and all percentage of cell viabilities above are expressed 
relative to the 100% control. The results shown represent three independent 
experiments. The relative viabilities of monolayer untreated HT29 versus HT29 
treated by phages were not statistically different by a Mann-Whitney test.   
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Cytotoxicity induced by phages after a 24 h exposure was also measured in spheroids using the 
CellTiter-Glo® 3D cell viability assay (Fig. 23). This assay tested the amount of ATP, which is 
proportional to the number of viable cells in 3D culture. HT29 spheroids were grown, treated 
with 108 PFU of wildtype and D::EGF phages for 24 h, and were assayed for cell viability.  
 
 
Figure 23:  HT29 spheroid cell viabilities relative to control in response to phage treatment. 
7-day old HT29 spheroids (seeding density: 5,000 cells) were treated with wildtype phages, Hi-
D::EGF phages or AlexaFluor488 tagged phages for 24 h. Cell viability of HT29 spheroids 
treated with phages were assessed by measuring ATP content and the luminescence output via 
the luciferase enzyme supplied in the ultra-Glo™ reagent. All viabilities are expressed as relative 
values to spheroids cultured normally with serum, which were considered to be 100% viable. 
The results shown represent four replicates. The relative viabilities of spheroids untreated HT29 
versus HT29 treated by phages were not statistically different by multiple comparisons one-way 




The mean cell viability was higher for HT29 spheroids exposed to wildtype phages than D::EGF 
phages (74% versus 54%). This result correlates to the brightfield images of HT29 spheroids that 
were smaller in size in response to D::EGF phages than wildtype phages (Fig. 18-21). The mean 
cell viabilities were similar between spheroids treated with diluted and undiluted wildtype and 
D::EGF phages. However, the results were reversed for phages following AlexaFluor488 tagging 
– spheroids applied with D::EGF phages had 79% viability, versus 49% for wildtype phages. 
Percentage of cell viability was analyzed by the multiple comparisons one-way ANOVA test, 
however, these results were not deemed statistically significant (p<0.05).   
4.7 Spheroid embedding and sectioning 
Spheroids grown for 7 d (seeding density of 5,000 cells) were treated for 24 h with AlexaFluor 
488 tagged phages, D::EGF and wildtype phages and were processed to visualize phage activity 
in the inner regions of the spheroid that were obscured in the confocal optical sections. Spheroids 
were sectioned, embedded onto glass slides and imaged with a fluorescent microscope. 
Fluorescent particles that may have been phage-related were found dispersed throughout the 
slides, unassociated with the spheroid sections (not shown). It was unclear whether these 
particles were background fluorescence or intra-tumoral fluorescent phages that have become 
unbound during the process of de-waxing. Therefore, our attempt to assess the depth of phage 






Chapter 5: Discussion 
Bacteriophages have emerged as potent and efficient tools in medicine, specifically with the 
advent of phage display technology. This technology has created new avenues for phages in 
cancer treatment as a means for targeted delivery into malignant cells and tissues in recent years. 
Their genetic flexibility to undergo surface modifications to target specific cells and tissue types 
have made them an attractive target in therapeutics.   
This was an exploratory study with the purpose of characterization of λ phages and their 
interaction with mammalian cells. Here, we discovered that λ phages naturally adhere to the 
surface of mammalian (mouse and human) cells and can accumulate in three-dimensional 
multicellular spheroids, in which both stromal and neoplastic cells of a tumour could be 
modeled.  
We chose HT29, which expresses the highest level of EGFR in relation to other colorectal cancer 
cell lines, to determine whether tumour growth was altered by the signal intervention with 
D::EGF phages (Matsuo et al., 2011b). They are also representative of wildtype-KRAS and 
BRAF-mutated tumours, which have been reported in approximately 5-15% of patients with 
colorectal cancers (Xu & Solomon, 1996; Yuen et al., 2002). EGF was the peptide of choice for 
display, as it retains its function when displayed on phage, and has been well-documented in 
targeting of other types of vectors in gene therapy applications (Roth & Cristiano, 1997; Souriau 
et al., 1997).  
5.2 Bacteriophage λ accumulates in multicellular spheroids 
The NIH3T3 spheroids employed in this project were relatively small, approximately 300 μm in 
diameter, and lacking the hypoxic regions exhibited by large, solid tumours. Despite the small 
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size, NIH3T3 spheroids provided a proof-of-concept for native interactions between λ phages 
and mammalian cells in the context of 3D culture, specifically for assessing the ability for 
adherence and penetration of the intercellular spaces. Fibroblasts are the most common type of 
cells of the connective tissue and synthesize the ECM, forming a structural network that is 
difficult to infiltrate in tissues. Confocal images showed the propensity of λ phages to adhere and 
accumulate between the fibroblasts. This implicates that phages may be able to penetrate through 
the network of connective tissues interposed between malignant cells and normal host tissues, 
which often structurally prevents the effective infiltration of nanoparticles.  
As all spheroids were thoroughly washed to discard unbound/weakly-bound phages, the phage-
associated fluorescence emitted on the surface of the spheroids evidences surface interaction 
between phages and fibroblasts. This is in accord with other findings arguing for inherent phage 
adherence to cancer cells in vivo and in vitro (Dabrowska et al., 2004, 2005). Green fluorescence 
associated with wildtype λ phages was observed throughout various cross-sections of NIH3T3 
spheroids. Phage adherence appeared to be time dependent; this was observed as early as 30 min, 
whereby small fluorescent green dots could be visualized at the rim of spheroids (Fig. 10). A 
major limitation of the confocal microscope was the inability to visualize dense inner regions of 
the spheroids. Fig. 10 shows evenly-distributed phage-associated fluorescence throughout visible 
regions in the optical sections at 24 h, rather than simply at peripheral cells of spheroids as seen 
at 6 h. At 24 h, phages have likely localized both inter- and intracellularly; while the exact nature 
of this interaction is unknown, this increase in positive signal over time, both in intensity and the 
areas covered, suggests a deeper infiltration and internalization of phages into the spheroids. 
More phages were likely able to accumulate on the surface of cells, as bound phages diffused 
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inwards into the spheroid, freeing up the surfaces of the cells for binding by phages. This would 
result in prevailing green fluorescence throughout the cross-sections as seen in Fig. 10. 
Next, we were interested in the interaction of phages and HT29 colon adenocarcinoma cells, 
which overexpress EGFR (Matsuo et al., 2011a). Using the dual control phage display system, 
maximally and minimally decorated D::EGF λ phages were generated and applied to HT29 
spheroids. These spheroids were consistently robust, possessing diameters of ~350 μm. As 
expected, D::EGF phages demonstrated greater accumulation within spheroids at 8 - 24 h than 
wildtype phages, which suggests that λ-EGF-EGFR association mediated this interaction (Fig. 
12-14). However, wildtype phages appeared to have interacted with the spheroids at an earlier 
time point of 4 h (Fig. 12, 13). This could be attributed to the overall bulkiness of the D::EGF 
phages; phages suspended in solution must rely on Brownian motion to come into contact with 
spheroids.  Wildtype phages, which do not carry an additional load, may be able to diffuse more 
rapidly to interact with the cells.  Prior study by Nicastro et al. compared sizes of λF7 phages 
displaying eGFP molecules under the permutations of various E. coli suppressor hosts and 
temperature by dynamic light scattering; phages grown on SupD at 37 °C (maximal display) was 
about 3 times greater in diameter than wildtype phages, which are approximately 62 nm in 
diameter and 150 nm in length (Hendrix & Duda, 1992). Phages grown on SupF at 37°C 
(minimal display) was about 1.6 times greater than the wildtype phages (Nicastro et al., 2013).  
Interestingly, wildtype phages appeared to have a better accumulation within NIH3T3 spheroids 
than HT29 spheroids, specifically at 24 h (Fig.10–13). This may be caused by differences in cell-
cell contacts found in different cell types. Epithelial cells are characterized by tight and 
adherence junctions that hinder the passage of molecules through the paracellular spaces between 
adjacent cells (Choi et al., 2013).  For example, one study showed 400-500 um human cervical 
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carcinoma (SiHa) spheroids consisted of tight junctions connecting neighbouring cells that 
restricted movement of materials, which was not observed with spheroids of other cell lines. 
Furthermore, ECM creates a physical barrier to prevent intratumoral drug penetration, and its 
composition can vary among different cell lines (Fechner et al., 1999; Görlach et al., 1994; Jain, 
1990; Kuh et al., 1999; Li et al.,2004; Pluen et al., 2001). Spheroids required collagenase 
treatment for effective penetration of nanoparticles greater than 100 nm (Svishchev & 
Goncharov, 1990). Hence, HT29 spheroids may consist of greater percentage of collagen or 
other ECM components than NIH3T3 spheroids, obstructing the penetration and accumulation of 
phages.   
Lastly, a raised concern in the analysis of fluorescent images was the possible dissociation of 
EGF molecules from the phage surface, which may lead us to mistake fragmented EGF 
molecules as infiltrated phage particles in the spheroids. Although this was not directly tested, 
the images of the fluorescently-tagged wildtype phages without EGF molecules fused to the 
surface provides a visual reference for the appearance of a positive signal. The pattern and 
appearance of fluorescence exhibited by D::EGF phages in Fig 12 & 13 were similar to those of 
wildtype phages. Additionally, EGF molecules are covalently linked to the capsid and therefore 
should form a stable product that is unlikely to dissociate from gpD (Aldred 2009; Sevier & 
Kaiser, 2002). EGF molecules are not likely proteolytically degraded in cell media, until phages 
are internalized and digested by the proteases in the lysosomes. The effect of pH, buffer and 
temperature on EGF stability were investigated by Yang et al. Maximum stability of recombinant 
human EGF (rhEGF) was from pH 6.0 to 8.0. rhEGF was shown to unfold at extreme pH 
conditions (pH < 4 and pH > 8) and thermal denaturation occurred at 40 – 76 °C (Yang et al., 
2004). Therefore, it is unlikely that EGF would have been cleaved or structurally modified in cell 
85 
 
media. Disassembly of λ phages was highly unlikely as well. Disassembly is characterized by the 
disruption of the λ capsid, which deactivates phages and inhibit infectivity (Qiu, 2012) Higher 
temperatures are detrimental for phage infectivity, affecting attachment, penetration and division 
in their bacterial hosts. However, it is unclear whether physical degradation of λ phages would 
occur over 24 h of incubation at 37 ᵒC, as half-lives of λ phages are 3.4 d at 37 ᵒC (Jepson & 
March, 2004). Qiu measured the melting transitions of λ particles and showed that λ head and 
DNA disassembly occurred at 87 ᵒC and 91 ᵒC, respectively, with no noticeable effects at room 
temperature (Qiu, 2012). The long tail of λ is more susceptible to mechanical shearing than the 
capsid, but this was also shown to occur above 68 ᵒC (Qiu, 2012). Furthermore, Ivanovska et al. 
demonstrated that wildtype λ capsids were relatively stiff when measured with atomic force 
microscopy (AFM) indentation technique, with the maximum deformation force equal to ~0.8 
nN (Ivanovska et al., 2007). pH levels can also greatly affect the physical stability of phages, as 
hydrogen ion concentrations can cause phages to coagulate; however, λ phages can tolerate a 
wide range of pH and have not shown significant decreases in titers at pH’s of 3 -11 at room 
temperature (Jepson & March, 2004). Other external conditions that can render phages 
physically unstable include incubation in ultrapure water, which can also cause head degradation 
and tail fragmentation of phages (Governal & Gerba, 1997); and low salt concentrations, which 
can increase the pressure of the packaged DNA, causing the capsid to burst open (Cordova et al., 
2003). SDS and phenol can chemically disrupt the λ capsid protein (Rau et al., 1984). Phages 
were not exposed to any of these conditions in this study. Therefore, incubations in cell media 
supplemented by 5% FBS at 37 ᵒC are unlikely to disrupt the λ capsid for EGF molecules to 
completely disengage from phages. While Table 4 demonstrates higher loss of infectivity of 
D::EGF phages at 37ᵒC in DMEM and 5% FBS to 19% of initial titers, it is not representative of 
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the loss of structural integrity of phages. This is not likely to prevent their visualization after 24 h 
of incubation, as D::EGF phages may still exist as EGF-expressing particles.   
5.3 EGF display enhances bacteriophage uptake into HT29 cells  
Monoclonal antibodies that target the extracellular domain of EGFR, such as cetuximab, are 
internalized with EGFR as antibody-receptor complexes. During this process, the receptor 
dimerizes, but downstream signaling events are not triggered (Berger, Madshus, & Stang, 2012). 
Similar cellular events were expected upon binding of D::EGF phages to EGFR.  
Certain green fluorescent particles appeared more yellow and diffuse in the confocal images. 
This suggested intracellular fluorescence from λ phages internalized by the HT29 cells (Fig. 15). 
CellTracker-cytosolic labeling does not obscure the green fluorescence emitted by internalized 
phages. Another study demonstrated that fluorescently-labeled organelles were visible via 
confocal microscopy, even though cells were co-stained with CellTracker Red (Gonzalez et al., 
2013).  
The recovery of D::EGF phages both intercellularly and intracellularly were greater than 
wildtype phages by almost two-folds at 30 minutes. This is in agreement with the confocal 
images showing phage localization (Table 7, Fig. 12-14). This was expected, as the EGF display 
would enhance the phage adherence to the HT29 cells. Ivanenkov et al. (1999) also showed that 
15-60 min is sufficient for cellular uptake of phages displaying ligands, which is also the length 
of incubation employed by Kim et al. (Kim et al., 2012). 30 min incubation in Fig. 17 may be the 
most representative time point to compare the differential rate of cellular uptake between 
D::EGF phages and wildtype λ phages, without the influence of intracellular phage degradation. 
Percentage of phage internalization was significantly greater for D::EGF phages at all time 
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points, but did not appear to correlate to the density of displayed EGF molecules. This does not 
agree with the study by Ivanenkov et al.; the uptake of filamentous phages with differential 
expression of integrin-binding peptides containing the RGD motif was dependent on the density 
of displayed peptides (Ivanenkov & Menon, 2000). Kassner et al. (1999) also stated similar 
findings, whereby transduction efficiency of multivalent EGF on the phage surface was much 
higher than no display of molecules (Kassner et al., 1999). A limitation in the technique we used 
to quantify internalized phages was the inability to completely remove or degrade extracellular 
phages. Despite the extensive washing of spheroids prior to the dissociation step, intracellular 
and extracellular phages were unable to be completely separated. Therefore, residual 
extracellular phages were most likely still included in the values in Fig. 17. Furthermore, it is 
important to note that the plaque assay does not precisely quantify total phages in stock solution 
and instead, general trends must be observed. While significant differences in titers such as those 
between EGF-displaying phages and wildtype phages (over 10-fold) can be noted, this assay may 
not be the most suitable to determine differences in recovered Lo-D::EGF and Hi-D::EGF 
phages.     
Wildtype λ phages and D::EGF phages are also likely to be internalized via caveosomes and/or 
clathrin-coated vesicles, as these vesicles can package particles of  500 and 200 nm, respectively. 
EGF is believed to primarily be internalized by pathways involving clathrin (Chem et al., 1990; 
Wiley, 1988). Internalization of M13 phages displaying cell-penetrating-peptide 3D8 VL 
transbody and TAT has been evidenced to be internalized through clathrin- and caveolae-
mediated endocytosis (Kim et al., 2012). Clathrin-mediated endocytosis has been shown to be 
involved in the uptake of larger M13 phages (900 nm length) packed very compactly; therefore, 
larger maximally-decorated D::EGF λ phages can be still packaged via vesicles. Although the 
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mechanism cannot be specified, wildtype λ phages may also bind to surface receptors of HT29 
cells for internalization. Non-specific electrostatic interactions with negatively-charged GAGs 
have been evidenced to serve as major cellular receptors for internalization of phages displaying 
TAT and 3D8 VL transbody (Kim et al., 2012). In this similar manner, the cationic amino acids 
(Lys and Arg) of gpD and gpE capsid proteins may be interacting biochemically with the 
negatively-charged carboxyl and sulfate groups present on GAGs. This may mediate phage-cell 
interaction and enable cellular uptake without the assistance of a displayed ligand. Moreover, 
there may be specific cell surface receptors that bind to unmodified, native phages. As previously 
mentioned, polysialic acid has been uncovered as a receptor for E. coli phage PK1A2. These 
phages were bound and internalized via the endolysosomal route and remained infective up to 24 
h (Lehti et al., 2017). Internalized phages have been shown to localize in the late 
endosomal/lysosomal compartments after 2 h, but some phages internalized via caveolae-
mediate endocytosis has been found to be released directly into the cytosol and remained 
infective without degradation (Ivanenkov & Menon, 2000; Lehti et al., 2017). Although the fate 
of internalized λ phages are unclear, the lysosomal route appears to be common, as the treatment 
of cells with lysosomotropic agent enhanced phage recovery for up to 8 h. This study requires 
follow-up experiments in order to determine the intracellular route and eventual fate of the 
internalized phages.  
 
 





EGF molecules displayed on λ phages likely bound to the EGFR on HT29 cells, preventing the 
downstream signaling events that promote spheroid growth. Monoclonal antibodies that bind to 
EGFR have been shown to successfully inhibit growth and induce apoptosis of HT29 by 
competitively inhibiting the binding of endogenous ligands and EGF-induced tyrosine kinase-
dependent EGFR phosphorylation (Gill et al., 1984; Harding & Burtness, 2005). Similarly, high 
concentration of maximally-decorated D::EGF phages appeared to slow cell proliferation and 
prevent complete cell-cell connections from forming, as shown in Fig. 18. Interestingly, this did 
not appear to be ligand density-dependent, as minimally-decorated D::EGF phages (Lo-D::EGF 
phages) did not influence spheroid growth and formation. Avidity of the receptor-ligand 
interaction between phages and cells may be a possible explanation. To conceptualize this, the 
larger size of each maximally-decorated D::EGF phage particle may enable the interaction with 
many cells simultaneously through greater density of EGF molecules. This would entrap phage 
particles between each cell, forming lattice-like structures composed of phages interposed 
between HT29 cells via EGF-EGFR connections. This would effectively and simultaneously 
block EGFRs on multiple cells, impeding any growth factors from reaching the receptors. 
Eventually, the rate of cell proliferation would overcome the EGFR block, as observed from later 
days. 
All spheroids treated with phages, including wildtype phages, exhibited smaller spheroids by day 
20 compared to the control (Fig. 18), most likely due to surface-bound phages blocking the 
potentiation of cell-cell interactions. This effect was also apparent when phages were co-seeded 
with cells (Figs 19 & 20). Lehti et al. posited that phage internalization via polysialic acid will 
induce biological changes in the cell because the turnover of cell surface polysialic acid will 
reduce the numbers of available on the surface, reducing its role in regulating cell interactions. 
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Similarly, we can expect that application of phages, which are subject to internalization, will 
induce changes in cell activities and ultimately affect spheroid formation.  
The signaling kinetics and the alteration of downstream effects to the treatment with D::EGF 
phages and their subsequent binding to EGFR on HT29 cells can only be speculated. It is likely 
that multiple cellular mechanisms are altered in response to the D:EGF-EGFR reaction. Cell 
proliferation appears to have slowed, which may be a result of the inactivation or reduced 
signaling of the Ras/MAPK pathway. This pathway is normally induced upon EGFR 
phosphorylation and the binding of Grb2 and Src homology 2 (Chattopadhyay et al,. 1999). 
Reduced cell survival is also implicated with the cells treated with D::EGF phages in Fig. 18, 
which suggests the involvement of EGFR in the PI(3)K/Akt pathway through adaptor protein 
Gab-1 (Mattoon et al., 2004). HT29 cell adhesion appears to also be lost in response to D::EGF 
phages as shown in Fig. 19 & 22, which may be a result of the loss in the ability of STAT3 from 
binding to the activated EGFR. Consequently, this would prevent STAT3 dimerization and 
translocation into the nucleus to regulate gene transcription to maintain epithelial cell polarity 
and adhesion (Bromberg, 2008). These results were not anticipated, as HT29 colon 
adenocarcinoma cells harbour the V600E BRAF heterozygotic mutation, which is often 
responsible for resistance (8.3%) to anti-EGFR therapy (Benlloch et al., 2006; De Roock et al., 
2010; Xu & Solomon, 1996). Mutations in BRAF V600E can allow for downstream signaling 
events to persist in the absence of signaling molecules, leading to constitutive cell survival and 
proliferation. However, this study has demonstrated that phages with a maximal display of EGF 
molecules will slow spheroid growth, most likely through the reduced cell proliferation and 
survival. The same effects were not exhibited when spheroids were treated with wildtype phages.  
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Follow-up studies on the cellular and molecular mechanisms altered in response to D::EGF 
phages are warranted.  
5.5 Bacteriophage λ is not cytotoxic to HT29 cells   
MTT assay (Fig. 22) did not show significant differences in the viability of monolayer HT29 
cells in response to phage application. Porayath et al. also reported that unmodified E. coli 
phages were not cytotoxic to HT29 cells in monolayer culture after 24 h by Resazurin assay. In 
this assay, the morphology of treated cells was similar to untreated cells (Porayath et al., 2018). 
D::EGF phages did not induce cytoxicity in the monolayer culture. This agrees with the findings 
of Solmi et al., which also revealed no statistically significant differences in HT29 cell viabilities 
in response to 24 h exposure to cetuximab (Solmi et al., 2008). In the 3D culture, cell viability 
was expected to be different as gene expression profiles are often different from monolayer 
cultures (Fig. 23). It was also expected to be more representative of in vivo HT29 tumour 
response to phages (Barbone et al., 2016). Wildtype phages did not significantly reduce the 
viability of HT29 spheroids after 24 h. D::EGF phages, however, reduced the mean of number of 
viable cells to 54% (Fig. 23). These results are in agreement with the brightfield images (Fig. 18 
- 21); spheroids demonstrated loose cell-cell connections and were smaller when treated with 
D::EGF phages. These spheroids consisted of fewer cells compared to the control in later stages, 
suggesting a slower cell proliferation and/or cell death (Fig. 18). 100-fold diluted mixtures of 
both D::EGF and wildtype phages resulted in similar levels of toxicity for the cells as the 
undiluted mixtures. The dilution of phages used in this experiment may not have been high 
enough to see correlating reduction in cytotoxicity as toxicity levels could plateau at certain 
concentrations of phages. Serial dilutions of phages must be added to the spheroids to see 
correlating reduction of viable cells, which will be confirmed in future studies.  
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Unexpectedly, results were reversed with phages that were labeled with AlexaFluor 488, with 
reduced viability in spheroids applied with wildtype phages. It is unclear what caused this – 
phage surface biochemistry may have been altered, changing the overall surface interactions with 
the HT29 cells. These toxicity assays confirm that wildtype phages are relatively inert in 
mammalian cells. However, the fusion of ligands may confer advantages such as specific 
targeting and reduction in viable cancer cells, enhancing their therapeutic potentials.  
The therapeutic potential of phages against solid tumours are promising as λ phages are able to 
interact with mammalian cells and accumulate in both spheroids and in cells. Phages can be 
genetically modified to display a targeting moiety on the surface for specificity; this can also 
slow growth by binding to plasma membrane receptors to induce/inhibit signalling events that 
result in changes in gene expression and cell growth regulation. The heterogeneity of tumours 











Chapter 6: Conclusion 
The intention of this work was to characterize bacteriophage λ and its interaction with cells in the 
context of three-dimensional culture. The number of applications for phages is growing in the 
field of cancer biology as well as the interest in developing a phage-based drug delivery system; 
however, the ability of phages to penetrate tightly packed cells in the tumour microenvironment 
has not been investigated to date. In this work, wildtype λ phages without any surface 
modifications and EGF-displaying λ phages have been compared for the adherence and 
penetration into HT29 colon adenocarcinoma spheroids, cellular uptake and impacts on spheroid 
growth. λ phages did not require ligand mediation to adhere to the surface of spheroids, although 
the display of EGF peptides on λ phages increased the level of phage-associated fluorescence on 
the surface of HT29 spheroids. Visualization of phages localized in the inner regions of 
spheroids was limited by confocal microscopy; however, phage-associated fluorescence was 
diffuse in all regions that were visible after 24 h in fibroblast spheroids. The significance of 
effective phage penetration and accumulation into spheroids is its potential to successfully 
traverse the dense tumour microenvironment composed of fibroblasts, immune cells and ECM, 
and potentially resulting in better biodistribution than other nanoparticles.   
EGF-displaying phages showed higher propensity to be internalized by the HT29 cells than 
wildtype λ phages. The implications for lambda phage internalization into mammalian cells is 
the potential for successful targeting of phages for gene delivery. However, one of the limiting 
steps of phages for gene delivery is nuclear localization, as phages are most likely routed to the 
lysosomes upon internalization. Lastly, the application of EGF-displaying phages in high 
concentrations showed interference in cell aggregation for spheroid formation, slowing its 
growth. This was most likely caused by the blocking of EGFR on HT29 cells and depriving the 
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cells of growth factors; this exposure to phages was shown to result in less viable cells in the 
spheroid. With ongoing progress made in the discovery of phage-mammalian cell interactions, 

















Chapter 7: Future Research Objectives 
Further controls are recommended in future experiments to supplement our findings. To confirm 
the role of EGF-displaying phages to enhance accumulation, internalization as well as slowing 
the growth of HT29 spheroid, experiments are recommended using the controls as outlined 
below: 
1) Repeat all the experiments using cell lines that do not overexpress EGFR, such as 
NIH3T3, and other carcinoma cell lines that overexpress EGFR. Similar outcomes – 
higher accumulation of EGF-displaying phages, greater percentage of internalization and 
slowing of spheroid growth – are expected for EGFR-overexpressing spheroids. If such 
results are observed to a lesser degree in NIH3T3 spheroids and other cell lines with less 
EGFR expression, then the interactions observed in our studies may be specific to 
carcinoma cells. This will be therapeutically advantageous in vivo, as EGF-displaying 
phages will not harm normal cells and accumulate specifically in EGFR-expressing 
tumour cells.   
2) Confirm the expression of EGFR on HT29 cells and quantify λ phages bound to EGFR 
via Western blot. Gene expression can be altered in cells in 3D culture. Conducting a 
Western blot will confirm that high EGFR expression is maintained at relatively high 
levels in HT29 spheroids. Additionally, a Western blot can confirm that the positive 
fluorescence observed with the confocal pictures is indeed, λ phages.  
3) Repeat experiments using EGF as a control. EGF will bind competitively and 
preferentially to EGFR expressed on HT29 cells. This would reduce the number of EGF-
displaying phages binding to HT29 cells. Less EGF-displaying phages would be retained 
in the spheroids as indicated by decrease in fluorescence by the confocal microscopy. 
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Cells are also expected to take on normal aggregation upon co-seeding with a high 
concentration of EGF-displaying phages. If EGFR is occupied by EGF, the treatment of 
spheroids with EGF-displaying phages would not lead to loose “gaps” between the 
intercellular spaces of spheroids, assuming that these gaps were caused by the infiltration 
of EGF-displaying phages. Additionally, there would be a smaller decrease in viability of 
HT29 cells in spheroids. This would confirm that the action of EGF-displaying phages 
observed in the performed experiments above was mediated specifically by the λ-EGF-
EGFR interaction. 
Other further studies include:  
1) Constructing a λ phage-derived vector engineered to carry a mammalian transgene 
cassette expressing GFP. Fluorescent-tagging of this vector, then their application to 
spheroids and subsequent visualization of GFP-expressing cells provides an 
understanding of the infiltration and transfection efficiency of a λ- based vector. This 
allows us to assess phages as a delivery vehicle though a dense, 3D cell culture.  
2) Perform RNA seq of HT29 cells in spheroids to determine differences in gene expression 
among untreated cells, cells in response to wildtype phages and EGF-displaying phages. 
This assay will elucidate the unknown mechanisms behind the cellular and molecular 
changes in response to phages. To date, the downstream pathways induced in response to 
EGF-displaying phages is unknown. It will be interesting to observe whether there are 
similarities in gene expression between cells treated with EGF-displaying phages and 
another inhibitor of the extracellular domain of EGFR, such as the mAb cetuximab. 
3) Perform a Live/Dead Cell Staining. A commercially available kit can differentially label 
intracellular proteins of live cells with a green fluorescent probe and late apoptotic and 
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necrotic cells with a red fluorescent probe. The 3D cytotoxicity assay performed in this 
study can be further supplemented with this staining assay. This will determine the region 
of cells in spheroids that have been impacted by the treatment with EGF-displaying 
phages and indicate where phages have localized in the spheroid.   
In the near future, we also hope to extend this study in vivo, applying EGF-displaying phages 
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